<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rifampin (rifampicin): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rifampin (rifampicin): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rifampin (rifampicin): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9864" href="/d/html/9864.html" rel="external">see "Rifampin (rifampicin): Drug information"</a> and <a class="drug drug_patient" data-topicid="11184" href="/d/html/11184.html" rel="external">see "Rifampin (rifampicin): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F218187"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rifadin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868150"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rifadin [DSC];</li>
<li>Rofact</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1049735"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Antitubercular Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462577"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection: </b>IV, Oral: 10 mg/kg/<b>day</b> every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cac9412-1bc5-4bec-b02a-a3a85fae32ae">
<i>H. influenzae</i>, chemoprophylaxis after close contact with a patient with invasive disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>H. influenzae</i>, chemo</b>
<b>prophylaxis after close contact with a patient with invasive disease:</b> Limited data available: IV, Oral: 10 mg/kg/<b>day</b> once daily for 4 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90864487-9e39-4ce2-91ad-23df7993a5a4">Meningococcal disease, chemoprophylaxis after close contact with a patient with invasive disease or elimination in asymptomatic carriers</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal disease, chemoprophylaxis after close contact with a patient with invasive disease or elimination in asymptomatic carriers:</b> IV, Oral: 10 mg/kg/<b>day</b> in divided doses every 12 hours for 2 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac23b7ce-10c5-47f3-8e23-ae9d3d724262">
<i>Staphylococcus</i> spp. infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Staphylococcus</i> spp. infections (adjunctive agent):</b> Limited data available: IV, Oral: 10 to 20 mg/kg/<b>day</b> in divided doses every 12 hours in combination with appropriate first-line antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23328960','lexi-content-ref-12162600','lexi-content-ref-8285624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23328960','lexi-content-ref-12162600','lexi-content-ref-8285624'])">Ref</a></span>). <b>Note:</b> Rifampin was most commonly reported in combination with vancomycin with or without an aminoglycoside and was continued for ~10 to 16 days; however, durations of 1 to 35 days have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16452352','lexi-content-ref-23328960','lexi-content-ref-12162600','lexi-content-ref-8285624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16452352','lexi-content-ref-23328960','lexi-content-ref-12162600','lexi-content-ref-8285624'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F218215"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing presented in mg/kg/dose and mg/kg/<b>day; </b>use caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Rifampin monotherapy is rarely indicated; most indications require combination therapy.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="822f7585-7e9e-4908-9ff6-6c5b006615db">Anaplasmosis, mild, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaplasmosis, mild, symptomatic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve use for patients with severe allergy or intolerance to doxycycline. Rifampin is not effective for Rocky Mountain spotted fever or Lyme disease. If concurrent Lyme disease is suspected, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27172113','lexi-content-ref-17029130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27172113','lexi-content-ref-17029130'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available: Oral: 20 mg/kg/<b>day</b> in 2 divided doses for 7 to 10 days; maximum dose: 300 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27172113','lexi-content-ref-17029130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27172113','lexi-content-ref-17029130'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd7ed646-84b1-40f1-9209-447ba8b70d5e">Brucellosis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brucellosis, treatment: </b>Limited data available: Children and Adolescents: Oral: 15 to 20 mg/kg/<b>day</b> in 1 to 2 divided doses as part of an appropriate combination regimen; maximum daily dose: 900 mg/<b>day</b>. Duration is ≥6 weeks and dependent on patient-specific factors including site of infection and presence of complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26706674','lexi-content-ref-Bradley.1','lexi-content-ref-CDC.2017','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26706674','lexi-content-ref-Bradley.1','lexi-content-ref-CDC.2017','lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ac94424-86c3-4a96-9144-c9b2d85ba3fa">Cholestatic pruritus, persistent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholestatic pruritus, persistent: </b>Limited data available: Infants ≥4 months, Children, and Adolescents: Oral: 4 to 10 mg/kg/<b>day</b> in 2 divided doses; maximum daily dose: 600 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2179027','lexi-content-ref-17401268','lexi-content-ref-8024298','lexi-content-ref-10512405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2179027','lexi-content-ref-17401268','lexi-content-ref-8024298','lexi-content-ref-10512405'])">Ref</a></span>). If no response, may increase dose by 2 mg/kg/<b>day</b> every 2 weeks to a maximum dose of 20 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401268'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da36b131-13ff-4e28-b905-1acb141aff64">Endocarditis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis:</b> Limited data available: <b>Note:</b> Use as part of an appropriate combination regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric therapy or culture-negative endocarditis (prosthetic valve/material) </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Early (≤1 year) prosthetic valve infection or nosocomial infection associated with vascular cannulation: Children and Adolescents: Oral, IV: 20 mg/kg/<b>day</b> divided every 8 hours; maximum daily dose: 900 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Late (&gt;1 year) prosthetic valve infection: Children and Adolescents: Oral, IV: 15 to 20 mg/kg/<b>day</b> divided every 12 hours; maximum daily dose: 600 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>MRSA endocarditis (prosthetic valve)</i>: Infants, Children, and Adolescents: Oral, IV: 15 mg/kg/<b>day</b> divided every 8 hours; maximum daily dose: 900 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9938d465-584f-48f7-8083-e90bc984c47e">Exit-site or tunnel infection, peritoneal dialysis catheter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exit-site or tunnel infection, peritoneal dialysis catheter:</b> Limited data available: Infants, Children, and Adolescents: Oral: 10 to 20 mg/kg/<b>day</b> divided into 2 doses as part of an appropriate combination regimen. Maximum dose: 600 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>). <b>Note:</b> Should not be used as monotherapy or routinely used in areas where tuberculosis (TB) is endemic.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eda89ebd-07c6-4c6d-9fd7-c2e8f29a13da">
<i>H. influenzae</i> disease, chemoprophylaxis after close contact with a patient with invasive disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>H. influenzae</b></i>
<b> disease, chemoprophylaxis after close contact with a patient with invasive disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 20 mg/kg/<b>day</b> once daily for 4 days; maximum dose: 600 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e8820e5-cd13-4b2d-840c-74174ab30524">Leprosy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leprosy:</b> Limited data available: <b>Note: </b>In the United States, it is strongly recommended to contact the National Hansen's Disease Program for management of leprosy in children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHDP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHDP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 10 to 20 mg/kg/<b>day </b>once daily; maximum dose: 600 mg/dose. If used in combination with prednisone, rifampin should be administered once monthly. Should be given as part of an appropriate combination regimen for 12 months for tuberculoid (paucibacillary) disease and 24 months for lepromatous (multibacillary) disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHDP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHDP.1'])">Ref</a></span>); in resource-limited settings, the World Health Organization allows for shorter durations of monthly dosing for 6 months (paucibacillary) or 12 months (multibacillary) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90864487-9e39-4ce2-91ad-23df7993a5a4">Meningococcal disease, chemoprophylaxis after close contact with a patient with invasive disease or elimination in asymptomatic carriers</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal disease, chemoprophylaxis after close contact with a patient with invasive disease or elimination in asymptomatic carriers:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 20 mg/kg/<b>day</b> in divided doses every 12 hours for 2 days; maximum dose: 600 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab4a56e4-32ec-4776-b503-ce1b14d69f67">
<i>Mycobacterium avium</i> complex infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Mycobacterium avium </i>complex infection:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary disease, nonsevere noncavitary nodular/bronchiectatic disease in patients without cystic fibrosis: </i>Children and Adolescents: Oral: 15 mg/kg/<b>dose</b> 3 times weekly as part of an appropriate combination regimen; maximum dose: 450 mg in patients weighing &lt;50 kg; maximum dose: 600 mg in patients weighing ≥50 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054853','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054853','lexi-content-ref-AAP.2'])">Ref</a></span>). <b>Note:</b> Three-times-weekly dosing has been shown to be as effective as daily dosing in adults with mild to moderate disease with fewer adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary disease, severe nodular/bronchiectatic disease, cavitary disease, or disease in patients with cystic fibrosis: </i>Children and Adolescents: Oral: 10 to 20 mg/kg/<b>day</b> once daily as part of an appropriate combination regimen; maximum dose: 450 mg in patients weighing &lt;50 kg; maximum dose: 600 mg in patients weighing ≥50 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054853','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054853','lexi-content-ref-26666259'])">Ref</a></span>). <b>Note:</b> Daily dosing is recommended in patients with cystic fibrosis due to lack of data to support intermittent dosing and uncertainty regarding absorption and lung penetration in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26666259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy: </i>Continue treatment until patient is culture negative on therapy for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054853','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054853','lexi-content-ref-26666259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2f0164e-28ab-4d30-b893-da899a8afeac">Peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis), treatment:</b> Infants, Children, and Adolescents: Oral: 10 to 20 mg/kg/<b>day</b> divided into 2 doses in combination with other appropriate antibiotics; maximum dose: 600 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7f382002-7265-4ae3-8486-c4b6f297062d">Streptococcus, group A; chronic carriage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; chronic carriage:</b> Limited data available: <b>Note:</b> Most individuals with chronic carriage do not require antibiotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with oral penicillin V</i>: Oral: 20 mg/kg/<b>day</b> once daily for the last 4 days of treatment; maximum daily dose: 600 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>In combination with intramuscular benzathine penicillin G</i>: Oral: 20 mg/kg/<b>day</b> in 2 divided doses for 4 days starting the day of the penicillin injection; maximum daily dose: 600 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026','lexi-content-ref-3889257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026','lexi-content-ref-3889257'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53bc9bf4-ed66-4900-b102-e4c801fc9f09">Tuberculosis, active; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, active (drug-susceptible); treatment </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Always administer in combination with other antitubercular drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-Manu.1'])">Ref</a></span>). Currently recommended doses in guideline, particularly those on the lower end of the range, may not achieve desired exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30588647','lexi-content-ref-25505005','lexi-content-ref-26407268','lexi-content-ref-28719501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30588647','lexi-content-ref-25505005','lexi-content-ref-26407268','lexi-content-ref-28719501'])">Ref</a></span>). Doses of 20 to 30 mg/kg/dose have been recommended for infants and young children or for treating disseminated tuberculosis or tuberculous meningitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial intensive phase:</i>
<b>Note:</b> Administer part of a standard 4-drug regimen for 2 months.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;15 years weighing ≤40 kg: Oral, IV: 10 to 20 mg/kg/dose once daily (or 5 days/week by directly observed therapy [DOT]); maximum dose: 600 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents ≥15 years: Oral, IV: 10 mg/kg/dose once daily (or 5 days/week by DOT); maximum dose: 600 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuation phase: </i>
<b>Note:</b> Administer in combination with isoniazid for ≥4 months; continuation phase duration should be longer for cavitary disease with positive cultures at completion of intensive phase (7 months), bone and joint disease (≥4 to 7 months), and CNS disease (7 to 10 months).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;15 years weighing ≤40 kg: Oral, IV: 10 to 20 mg/kg/dose once daily (or 5 days/week by DOT); maximum dose: 600 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents ≥15 years: Oral, IV: 10 mg/kg/dose once daily (or 5 days/week by DOT); maximum dose: 600 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternative dosing intervals: </i>Daily or 5-times-weekly dosing is preferred, particularly during the intensive phase and in patients with HIV. If neither is feasible, daily (or 5-times-weekly) dosing for the intensive phase followed by 3-times-weekly dosing during the continuation phase may be considered. Directly observe therapy for any regimen that is &lt;7 days/week dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>). <b>Note:</b> 3-times-weekly dosing for the duration of treatment and twice-weekly dosing during the continuation phase are associated with worse outcomes compared to daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203783'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cc4b7ff-370a-47a0-abc7-37f2dedcc154">Tuberculosis, latent infection; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, latent infection; treatment:</b> Infants, Children, and Adolescents: Independent of HIV status: Oral: 15 to 20 mg/kg/<b>day</b> once daily; maximum dose: 600 mg/dose; use in combination with isoniazid for 3 months or as monotherapy for 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30067928','lexi-content-ref-HHS.3','lexi-content-ref-32053584','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30067928','lexi-content-ref-HHS.3','lexi-content-ref-32053584','lexi-content-ref-AAP.2'])">Ref</a></span>). Higher doses of 20 to 30 mg/kg/dose have been recommended for infants and young children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159839"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, based on experience in adults, dosage adjustment is likely unnecessary.</p></div>
<div class="block dohp drugH1Div" id="F51159840"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Baseline hepatic impairment</i>: There are no dosage adjustments provided in the manufacturer's labeling; use with caution. If hepatic function worsens, discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during therapy:</i> Discontinue therapy.</p></div>
<div class="block doa drugH1Div" id="F218192"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9864" href="/d/html/9864.html" rel="external">see "Rifampin (rifampicin): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1267b0a6-c3ad-408c-94f4-e9f0d52aba24">Anaplasmosis, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaplasmosis, symptomatic (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for patients with severe allergy or intolerance to doxycycline. Rifampin is not effective for Rocky Mountain spotted fever or Lyme disease. If concurrent Lyme disease is suspected, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27172113','lexi-content-ref-17029130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27172113','lexi-content-ref-17029130'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg twice daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27172113','lexi-content-ref-17029130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27172113','lexi-content-ref-17029130'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="452a5fca-911d-417a-b625-1b0f7a95ccab">
<i>Bartonella</i> spp. infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Bartonella</i> spp. infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bacteremia with or without endocarditis</i>
<i>: </i>
<b>Oral, IV:</b> 300 mg twice daily in combination with doxycycline for 14 days (without endocarditis) or 6 weeks (with endocarditis), followed by doxycycline monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-15155180','lexi-content-ref-Spach.2020a','lexi-content-ref-Spach.2020b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-15155180','lexi-content-ref-Spach.2020a','lexi-content-ref-Spach.2020b'])">Ref</a></span>). Some experts do not suggest rifampin as part of the regimen for patients with HIV and bacteremia without endocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other severe infection (including CNS infection) in patients with HIV: </i>
<b>Oral, IV:</b> 300 mg twice daily as part of an appropriate combination regimen. Duration of therapy is at least 3 months and depends on clinical course. <b>Note:</b> For CNS infection, use of adjunctive rifampin is optional (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cat scratch disease, lymphadenitis (alternative agent):</i>
<b>Oral:</b> 300 mg twice daily for 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.2020c']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.2020c'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cat scratch disease, disseminated in patients without HIV (hepatosplenic, prolonged systemic febrile illness, CNS infection, neuroretinitis):</i>
<b>Oral, IV:</b> 300 mg twice daily as part of an appropriate combination regimen. Duration is 10 to 14 days for hepatosplenic disease, prolonged systemic febrile illness, or CNS infection, and 4 to 6 weeks for neuroretinitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15155180','lexi-content-ref-Spach.2020c']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15155180','lexi-content-ref-Spach.2020c'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49929a72-f7cf-4de4-8d52-7a1d857c693e">Brucellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brucellosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i>
<b>Oral:</b> 600 to 900 mg once daily as part of an appropriate combination regimen. Duration is 6 weeks for uncomplicated nonfocal infection and at least 12 weeks for spondylitis, neurobrucellosis, and endocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18539496','lexi-content-ref-18162038','lexi-content-ref-Bosilkovski.1','lexi-content-ref-CDC.2017','lexi-content-ref-28143754','lexi-content-ref-18321957','lexi-content-ref-10585793','lexi-content-ref-Corbel.2006','lexi-content-ref-28768443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18539496','lexi-content-ref-18162038','lexi-content-ref-Bosilkovski.1','lexi-content-ref-CDC.2017','lexi-content-ref-28143754','lexi-content-ref-18321957','lexi-content-ref-10585793','lexi-content-ref-Corbel.2006','lexi-content-ref-28768443'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis (high-risk laboratory exposure):</i>
<b>Note: </b>For exposure to <i>Brucella abortus</i> RB51, use an alternative prophylactic regimen due to resistance.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 600 mg once daily in combination with doxycycline for 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bosilkovski.1','lexi-content-ref-CDC.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bosilkovski.1','lexi-content-ref-CDC.2017'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d43fded9-a360-4040-806e-8e684a927555">Cholestatic pruritus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholestatic pruritus (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use in patients with a baseline bilirubin &gt;2.5 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30070375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30070375'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 150 to 300 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Poupon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Poupon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Staphylococcus spp. or early (&lt;1 year) culture negative (prosthetic valve): </i>
<b>Oral, IV:</b> 900 mg/day in 3 equally divided doses as part of an appropriate combination regimen for ≥6 weeks; delay initiation of rifampin until 3 to 5 days after initiation of the other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316','lexi-content-ref-21217178','lexi-content-ref-Karchmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316','lexi-content-ref-21217178','lexi-content-ref-Karchmer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>S. aureus, methicillin-susceptible, oral step-down therapy for patients who inject drugs: </i>
<b>Note:</b> Not first-line therapy; data are limited. Reserve use for patients who inject drugs who had initial clinical improvement with IV treatment but cannot complete IV standard of care therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-30152252','lexi-content-ref-35139280','lexi-content-ref-36052413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-30152252','lexi-content-ref-35139280','lexi-content-ref-36052413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 600 mg twice daily in combination with dicloxacillin or linezolid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-30152252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-30152252'])">Ref</a></span>) <b>or</b> 300 mg 3 times daily in combination with ciprofloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-8686718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-8686718'])">Ref</a></span>) for a total duration, including initial IV therapy, of 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-30152252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-30152252'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1a5c771-d06c-4f42-a40c-2a0c6db81cba">Hidradenitis suppurativa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hidradenitis suppurativa (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 600 mg/day in 1 or 2 divided doses in combination with clindamycin for 10 to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30872149','lexi-content-ref-27753139','lexi-content-ref-19590173','lexi-content-ref-26831295','lexi-content-ref-19590174']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30872149','lexi-content-ref-27753139','lexi-content-ref-19590173','lexi-content-ref-26831295','lexi-content-ref-19590174'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1da0cc9-ed90-49e2-919d-713b985a3ab3">Leprosy, postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leprosy, postexposure prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For persons who have been in close contact with the patient with leprosy for ≥20 hours per week for &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.8']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.8'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>600 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18332051','lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18332051','lexi-content-ref-WHO.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff2bef78-2d94-40d1-9a8f-17f7cf460e7a">Leprosy, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leprosy, treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 600 mg once daily as part of an appropriate combination regimen for 12 months for tuberculoid (paucibacillary) disease and 24 months for lepromatous (multibacillary) disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHDP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHDP.1'])">Ref</a></span>). <b>Note:</b> Rifampin is given once monthly if coadministered with prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHDP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHDP.1'])">Ref</a></span>). For resource-limited settings, the World Health Organization recommends 600 mg once monthly as part of an appropriate combination regimen for 6 months (paucibacillary) or 12 months (multibacillary) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee503525-0e5d-4809-a500-384b58e44e0a">Meningococcal disease, chemoprophylaxis after close contact with a patient with invasive disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal disease, chemoprophylaxis after close contact with a patient with invasive disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 600 mg twice daily for 2 days. <b>Note:</b> Administer prophylaxis as soon as possible following exposure (ideally &lt;24 hours after identification of index patient). Close contacts include persons with prolonged exposure (≥8 hours) in close proximity (&lt;3 feet) to index patient or direct exposure to oral secretions (eg, household contacts, childcare center contacts) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-15917737','lexi-content-ref-23515099','lexi-content-ref-17021322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-15917737','lexi-content-ref-23515099','lexi-content-ref-17021322'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3c1ffc1-3b2c-44e1-abea-6af15373b052">Mycobacterial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial (nontuberculous) (eg, <i>M. avium</i> complex) infection (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary disease, nonsevere noncavitary nodular/bronchiectatic disease in patients without cystic fibrosis:</i>
<b>Oral:</b> 600 mg 3 times weekly as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-29054853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-29054853'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary disease, severe nodular/bronchiectatic disease, cavitary disease, or disease in patients with cystic fibrosis:</i>
<b>Oral:</b> 600 mg once daily as part of an appropriate combination regimen; reduce dose to 450 mg once daily for patients weighing &lt;50 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-26666259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> Continue treatment until patient is culture negative on therapy for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-29054853','lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-29054853','lexi-content-ref-26666259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d144717-343c-4e9f-9554-bcf47f1aabac">Staphylococcus spp. infections, including bone and joint and CNS</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Staphylococcus spp. infections, including bone and joint and CNS (adjunctive agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Used primarily in the setting of retained hardware or other prosthetic material for activity against biofilm formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178','lexi-content-ref-9605897','lexi-content-ref-30455229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178','lexi-content-ref-9605897','lexi-content-ref-30455229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 600 mg once daily <b>or</b> 300 to 450 mg twice daily in combination with an appropriate antistaphylococcal agent(s). Duration varies based on patient-specific factors, infection site, and intervention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.1','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.1','lexi-content-ref-21217178'])">Ref</a></span>). Some experts suggest delaying initiation of rifampin until several days after initiation of other antistaphylococcal agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-Osmon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76fe8f2e-2a7e-4f53-b40b-4ad4077a6e34">Streptococcus chronic carriage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus (group A) chronic carriage (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Most individuals with chronic carriage do not require antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 600 mg/day in 1 or 2 divided doses for the last 4 days of treatment in combination with penicillin V (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3919171','lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3919171','lexi-content-ref-22965026'])">Ref</a></span>) <b>or</b> for 4 days in combination with single-dose IM benzathine penicillin G (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026','lexi-content-ref-3889257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026','lexi-content-ref-3889257'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a14e477-5eab-40b1-b158-a6ebc65a1f53">Tuberculosis disease [active tuberculosis]</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis disease [active tuberculosis]: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Always administer in combination with other antitubercular drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382','lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382','lexi-content-ref-31729908'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Drug-susceptible:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Initial intensive phase: <b>Oral, IV: </b>10 mg/kg (maximum dose: 600 mg) once daily (or 5 days per week by directly observed therapy [DOT]) as part of a standard 4-drug regimen for 2 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuation phase: <b>Oral, IV: </b>10 mg/kg (maximum dose: 600 mg) once daily (or 5 days per week by DOT) in combination with isoniazid for at least 4 months or longer for cavitary disease with positive cultures (7 months), bone and joint disease (6 to 9 months), and CNS disease (≥12 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Alternative dosing intervals: Daily or 5-times-weekly dosing is preferred, particularly during the intensive phase. If neither is feasible, may consider daily (or 5-times-weekly) dosing for the intensive phase followed by 3-times-weekly dosing during the continuation phase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>); 3-times-weekly dosing for the duration of treatment and twice-weekly dosing during the continuation phase are associated with worse outcomes compared to daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203783'])">Ref</a></span>). Use DOT for &lt;7 days/week dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27516382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Isoniazid-resistant, rifampin-susceptible:</i>
<b>Oral/IV:</b> 10 mg/kg (maximum dose: 600 mg) once daily as part of an appropriate combination regimen. Expert consultation for optimal regimen and duration of treatment is advised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-WHO.7','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-WHO.7','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="23421342-4ccb-47f4-86a2-b61c9f7f4821">Tuberculosis infection [latent tuberculosis]</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis infection [latent tuberculosis]:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg/kg (maximum dose: 600 mg) once daily as a single agent for 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-32053584'])">Ref</a></span>) or in combination with isoniazid for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32053584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32053584'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991245"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>At rifampin doses ≤600 mg/day, reduced clearance by the kidney is compensated for by biliary excretion. However, at rifampin doses ≥900 mg/day, the hepatic excretory pathway is saturated and higher concentrations of rifampin are noted in patients with reduced kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7028436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7028436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;15 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: No dosage adjustment necessary for usual indication-specific doses ≤600 mg/day. For usual indication-specific doses ≥900 mg/day, consider limiting dose to 600 mg/day or monitoring more closely for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7028436','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7028436','lexi-content-ref-Expert.DOR'])">Ref</a></span>) except when used for meningococcal chemoprophylaxis (no adjustment necessary due to short duration of therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10228130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10228130'])">Ref</a></span>); no dosage adjustment necessary for usual indication-specific doses ≤600 mg/day. For usual indication-specific doses ≥900 mg/day, consider limiting dose to 600 mg/day or monitoring more closely for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7028436','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7028436','lexi-content-ref-Expert.DOR'])">Ref</a></span>) except when used for meningococcal chemoprophylaxis (no adjustment necessary due to short duration of therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12968844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12968844'])">Ref</a></span>); no dosage adjustment necessary for usual indication-specific doses ≤600 mg/day. For usual indication-specific doses ≥900 mg/day, consider limiting dose to 600 mg/day or monitoring more closely for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7028436','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7028436','lexi-content-ref-Expert.DOR'])">Ref</a></span>) except when used for meningococcal chemoprophylaxis (no adjustment necessary due to short duration of therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26518065','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26518065','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988495"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">There are no dosage adjustments provided in manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">New or worsening hepatic damage: Discontinue rifampin.</p></div>
<div class="block arsc drugH1Div" id="F55748046"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection (CDI) has occurred, including <b>
<i>Clostridioides difficile-</i>associated diarrhea</b> (in one case in a patient receiving concurrent clindamycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30142743']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30142743'])">Ref</a></span>) and <b>
<i>Clostridioides difficile</i> colitis</b>. Antituberculosis medications, such as rifampin have rarely been associated with CDI. Additionally, rifampin may decrease the risk of CDI from higher risk antibiotics (eg, clindamycin) and has been used in the treatment of CDI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30142743']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30142743'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospitalization or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors and H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Decreased hemoglobin</b>, <b>disorder of hemostatic components of blood </b>(vitamin K-dependent), <b>disseminated intravascular coagulation</b>, <b>eosinophilia</b>, <b>hemolysis</b>, <b>hemolytic anemia</b>, <b>hemorrhage</b>, <b>leukopenia</b>, <b>thrombocytopenia</b> (especially with high-dose therapy) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22302861','lexi-content-ref-30567221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22302861','lexi-content-ref-30567221'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; likely immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22302861','lexi-content-ref-30567221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22302861','lexi-content-ref-30567221'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; with intermittent dosing, reactions have occurred within 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22302861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22302861'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Intermittent exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22302861','lexi-content-ref-30567221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22302861','lexi-content-ref-30567221'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity of hepatocellular, cholestatic, and mixed patterns have been reported; may include asymptomatic <b>abnormal hepatic function tests</b>, isolated <b>jaundice </b>or<b> hyperbilirubinemia</b>, symptomatic self-limited <b>hepatitis</b>, or fulminant <b>hepatic failure</b> and death. Severe reactions, including fatalities, have occurred in patients with preexisting hepatic failure and in patients receiving concurrent hepatotoxic agents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; possible mechanisms include hypersensitivity or metabolic idiosyncratic reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17021358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17021358'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Most cases occurred within 4 weeks in one study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32989000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32989000'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32989000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32989000'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17995946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17995946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17995946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17995946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other hepatotoxic agents (eg, isoniazid, pyrazinamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17995946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17995946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17995946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17995946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body mass index (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17995946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17995946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Malnutrition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17995946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17995946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting liver disease (eg, chronic viral hepatitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17995946','lexi-content-ref-17052297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17995946','lexi-content-ref-17052297'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17995946','lexi-content-ref-17052297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17995946','lexi-content-ref-17052297'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, both immediate (<b>urticaria</b>, <b>angioedema</b>, <b>anaphylaxis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16514245','lexi-content-ref-23060374','lexi-content-ref-24918746','lexi-content-ref-24275373','lexi-content-ref-26603634']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16514245','lexi-content-ref-23060374','lexi-content-ref-24918746','lexi-content-ref-24275373','lexi-content-ref-26603634'])">Ref</a></span>) and delayed have been reported. <b>Flu-like symptoms</b> or more severe shock-like syndrome may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16514245','lexi-content-ref-32014989','lexi-content-ref-17715477','lexi-content-ref-10575418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16514245','lexi-content-ref-32014989','lexi-content-ref-17715477','lexi-content-ref-10575418'])">Ref</a></span>). Delayed hypersensitivity reactions range from maculopapular <b>skin rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10575418','lexi-content-ref-33539388','lexi-content-ref-29410254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10575418','lexi-content-ref-33539388','lexi-content-ref-29410254'])">Ref</a></span>) and <b>fixed drug eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2147086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2147086'])">Ref</a></span>) to rare severe cutaneous adverse reactions, including <b>acute generalized exanthematous pustulosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16911558']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16911558'])">Ref</a></span>), <b>drug reaction with eosinophilia and systemic symptoms </b>(DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29274824','lexi-content-ref-30755272','lexi-content-ref-31021423','lexi-content-ref-29776648','lexi-content-ref-24450829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29274824','lexi-content-ref-30755272','lexi-content-ref-31021423','lexi-content-ref-29776648','lexi-content-ref-24450829'])">Ref</a></span>), <b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30083412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30083412'])">Ref</a></span>). Since rifampin is usually administered as part of a multidrug regimen, causality is difficult to determine in most cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30704698','lexi-content-ref-28060046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30704698','lexi-content-ref-28060046'])">Ref</a></span>). <b>Hypersensitivity angiitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20224679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20224679'])">Ref</a></span>) and <b>lichenoid eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25323272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25323272'])">Ref</a></span>) have also occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions: Non–dose-related; likely immunologic (ie, IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30275849'])">Ref</a></span>), although angioedema may be caused by a non–IgE-mediated mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24275373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24275373'])">Ref</a></span>). The flu-like syndrome may be caused by circulating antibodies complexing with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16514245','lexi-content-ref-24587958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16514245','lexi-content-ref-24587958'])">Ref</a></span>) or direct toxic effect of the drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10575418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10575418'])">Ref</a></span>). Delayed hypersensitivity reactions: Non–dose-related; immunologic (ie, involving a T-cell mediated drug-specific immune response) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-27373553']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-27373553'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-NICE.1'])">Ref</a></span>). Some cases of urticaria associated with rifampin have been delayed occurring 2 to 3 weeks after initiation of drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16514245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16514245'])">Ref</a></span>). Flu-like syndrome generally occurs within 1 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10575418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10575418'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; typically occur days to 8 weeks after drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16911558','lexi-content-ref-26120552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16911558','lexi-content-ref-26120552'])">Ref</a></span>), but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-24450829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-24450829'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose: Flu-like syndrome is considered dose-dependent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16503745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16503745'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Intermittent regimen: Flu-like syndrome occurs more frequently with intermittent regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16503745','lexi-content-ref-17715477','lexi-content-ref-25904367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16503745','lexi-content-ref-17715477','lexi-content-ref-25904367'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12569078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12569078'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HIV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12569078']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12569078'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Conflicting reports of cross-reactivity with rifabutin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24243988','lexi-content-ref-32169513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24243988','lexi-content-ref-32169513'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Potentially fatal <b>interstitial pulmonary disease</b> has been reported, including <b>pneumonitis, hypersensitivity pneumonitis, eosinophilic pneumonitis, pulmonary infiltrates, acute respiratory distress syndrome, bronchiolitis obliterans organizing pneumonia, and pulmonary fibrosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14665784','lexi-content-ref-32840240','lexi-content-ref-30755272','lexi-content-ref-23411704','lexi-content-ref-30755272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14665784','lexi-content-ref-32840240','lexi-content-ref-30755272','lexi-content-ref-23411704','lexi-content-ref-30755272'])">Ref</a></span>). Patients with rifampin-induced pneumonitis typically present with low-grade fever and shortness of breath with or without cough (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32840240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32840240'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; possibly immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23411704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23411704'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Pneumonitis: Varied; 3 days to 13 weeks in a bimodal pattern with early and late onset but difficult to determine as fever is a common symptom in patients undergoing tuberculosis therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23411704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23411704'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F218149"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Decreased blood pressure, facial edema (Holdiness 1989), flushing, hypersensitivity angiitis (Kim 2010), peripheral edema, shock (Luzzati 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Azad 2006), cutaneous lupus erythematosus (Patel 2001), erythema multiforme, lichenoid eruption (Shahul 2016), pemphigoid reaction, pruritus (Farah 2012), psoriasiform eruption (Feng 2020), skin rash (Farah 2012; Shin 2021), Stevens-Johnson syndrome (Collado-Chagoya 2019), toxic epidermal necrolysis (Collado-Chagoya 2019), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (Denny 2016; Elansary 1983), increased uric acid, menstrual disease</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, anorexia, cholestasis, <i>Clostridioides difficile-</i>associated diarrhea (Bessaleli 2018), <i>Clostridioides difficile</i> colitis, diarrhea, epigastric discomfort, flatulence, glossalgia, heartburn, nausea, staining of tooth (Ayaslioglu 2005), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (Covic 2004; Martins 2013), hemoglobinuria (Covic 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute intravascular hemolysis (Sanwal 2020), agranulocytosis (Andres 2017), decreased hemoglobin (Havey 2012; Sveroni 2018), disorder of hemostatic components of blood (vitamin K-dependent) (Havey 2012), disseminated intravascular coagulation (Havey 2012), eosinophilia, hemolysis (Havey 2012; Sveroni 2018), hemolytic anemia (Havey 2012; Sveroni 2018), hemorrhage (Havey 2012), leukopenia, thrombocytopenia (especially with high-dose therapy) (Forget 2006), thrombotic microangiopathy (including hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura) (Gupta 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (Tostmann 2008), hepatic cirrhosis (Tostmann 2008), hepatic failure (Tostmann 2008), hepatitis (including shock-like syndrome with hepatic involvement) (Tostmann 2008), hepatotoxicity (Nelson 2014), hyperbilirubinemia (Tostmann 2008), jaundice (Tostmann 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Syrigou 2016), angioedema (Farah 2012), fixed drug eruption (Mimouni 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Brockhaus 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, behavioral changes, cerebral hemorrhage (Koboyashi 2002), confusion, dizziness, drowsiness, fatigue, headache, lack of concentration, myasthenia, numbness, psychosis (Salafia 1992), sore mouth</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain, myopathy (Forget 2006; Jenkins 1981)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Rossert 2001), acute renal injury, increased blood urea nitrogen, renal insufficiency, renal tubular necrosis (Forget 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome (Ashitani 2003), bronchiolitis obliterans organizing pneumonia, eosinophilic pneumonitis, dyspnea, flu-like symptoms (Luzzati 2007), hypersensitivity pneumonitis (Brockhaus 2019), interstitial pulmonary disease, pneumonitis (Ata 2020; Koma 2013), pulmonary fibrosis (Umeki 1988), pulmonary infiltrates, wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, paradoxical reaction (recurrence or appearance of new infection symptoms; may be transient)</p></div>
<div class="block coi drugH1Div" id="F218166"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to rifampin, any rifamycins, or any component of the formulation; concurrent use of atazanavir, darunavir, fosamprenavir, lurasidone, praziquantel, ritonavir/saquinavir, saquinavir, or tipranavir.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Jaundice associated with reduced bilirubin excretion; premature and newborn infants; breastfeeding women; hepatic function impairment.</p></div>
<div class="block war drugH1Div" id="F218146"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: Use with caution in patients with diabetes mellitus; management of diabetes may be more difficult in patients taking rifampin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Meningococcal disease: Do not use for treatment of meningococcal disease, only for short-term treatment of asymptomatic carrier states.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with porphyria; exacerbations have been reported due to enzyme-inducing properties.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Compliance: Monitor for compliance in patients on intermittent therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lenses: Remove soft contact lenses during therapy since permanent staining may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discoloration: Teeth (may be permanent), urine, feces, saliva, sweat, and tears may be discolored (yellow, orange, red, or brown).</p></div>
<div class="block foc drugH1Div" id="F218158"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rifadin: 150 mg [DSC], 300 mg [DSC] [contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rifadin: 600 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rifadin: 600 mg (1 ea) [contains sodium formaldehyde sulfoxylate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 600 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F218142"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F218168"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (rifAMPin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $3.24 - $9.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $4.59 - $11.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Rifadin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $214.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (rifAMPin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $183.60 - $192.63</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868151"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rifadin: 150 mg [DSC], 300 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rofact: 150 mg, 300 mg</p></div>
<div class="block exp drugH1Div" id="F218164"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>25 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2022)</p>
<p style="text-indent:-2em;margin-left:2em;">A 25 mg/mL oral suspension may be made with capsules and one of three different vehicles (a 1:1 mixture of Ora-Sweet and Ora-Plus, a 1:1 mixture of Ora-Sweet SF and Ora-Plus, or cherry syrup concentrate diluted 1:4 with Simple Syrup, NF). Empty the contents of ten 300 mg capsules into a mortar and reduce to a fine powder. Add 20 mL of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well," "protect from light," and "refrigerate." Stable for 28 days refrigerated (preferred) or at room temperature (Allen 1998; Nahata 2014).</p>
<div class="reference">Allen LV Jr, Erickson MA. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm</i>. 1998;55(17):1804-1809.<span class="pubmed-id">9775343</span></div>
<div class="reference">Nahata MC and Pai VB. <i>Pediatric Drug Formulations.</i> 6th ed. Cincinnati, OH: Harvey Whitney Books Co; 2014.</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>10 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 10 mg/mL oral suspension may be made with capsules and one of four different vehicles (Simple Syrup [Syrup NF], Simple Syrup [Humco Laboratories], SyrPalta Syrup [Emerson Laboratories], or Raspberry Syrup [Humco Laboratories]). Empty the contents of four 300 mg capsules <b>or </b>eight 150 mg capsules onto a piece of weighing paper. If necessary, crush contents to produce a fine powder. Transfer powder to a 4 oz amber glass or plastic (high-density polyethylene [HDPE], polypropylene, or polycarbonate) bottle. Rinse paper and spatula with 20 mL of chosen vehicle, add rinse to bottle, and shake vigorously. Add 100 mL of same vehicle to bottle to make a total of 120 mL and shake vigorously. Stable for 28 days at room temperature (25°C ± 3°C) or refrigerated (2°C to 8°C); shake well prior to use.</p>
<div class="reference">Rifadin capsules and Rifadin IV (rifampin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2023.</div>
<p style="text-indent:-2em;margin-left:2em;">A 10 mg/mL oral suspension may be made with capsules and Simple Syrup, NF. Empty the contents of four 300 mg capsules into a mortar. If necessary, crush contents to produce a fine powder. Add 20 mL of Simple Syrup, NF and mix to a uniform paste; mix while adding simple syrup in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with simple syrup, and add quantity of vehicle sufficient to make 120 mL. Label "shake well." Stable for 42 days at room temperature (Nahata 2014).</p>
<div class="reference">Nahata MC and Pai VB. <i>Pediatric Drug Formulations.</i> 6th ed. Cincinnati, OH: Harvey Whitney Books Co; 2014.</div>
</div>
<div class="block admp drugH1Div" id="F52613816"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer on an empty stomach with a full glass of water (ie, 1 hour prior to or 2 hours after meals) to increase total absorption (food may delay and reduce the amount of rifampin absorbed). The compounded oral suspension must be shaken well before using. May mix contents of capsule with applesauce, pudding, or other semisoft foods (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer by slow IV infusion over 30 minutes to 3 hours. Do not administer IM or SUBQ. Avoid extravasation.</p></div>
<div class="block adm drugH1Div" id="F218162"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer IV preparation by slow IV infusion over 30 minutes to 3 hours at a final concentration not to exceed 6 mg/mL. Do <b>not</b> administer IM or SUBQ.</p>
<p style="text-indent:-2em;margin-left:4em;">May be an irritant; avoid extravasation. Restart infusion at another site if extravasation occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer on an empty stomach (ie, 1 hour prior to, or 2 hours after meals or antacids) to increase total absorption. The compounded oral suspension must be shaken well before using. May mix contents of capsule with applesauce or jelly.</p></div>
<div class="block sts drugH1Div" id="F218180"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); avoid excessive heat.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vials at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); avoid excessive heat (&gt;40°C [104°F]). Protect the intact vials from light. Reconstituted vials are stable for 30 hours at room temperature. Stability of parenteral admixture at room temperature (25°C [77°F]) is 8 hours for D5W or 6 hours for NS. <b>Note:</b> As of July 2018, the storage of reconstituted vials was changed from 24 hours to 30 hours at room temperature, the stability when admixed in D5W was changed from 4 hours to 8 hours, and the stability when admixed in NS from 24 hours to 6 hours in the Rifadin prescribing information. Similar changes may not be reflected in the Rifadin prescribing information for product distributed prior to July 2018 or in generic manufacturer's labeling.</p></div>
<div class="block usep drugH1Div" id="F53568685"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of all forms of tuberculosis in combination with other agents (FDA approved in pediatric patients [age not specified] and adults); elimination of meningococci from the nasopharynx in asymptomatic carriers (FDA approved in all ages). Has also been used for treatment of anaplasmosis, treatment of cholestatic pruritus, and prophylaxis in contacts of patients with invasive <i>Haemophilus influenzae</i> type B infection. In combination with other agents, has also been used for treatment of brucellosis, treatment of endocarditis, treatment of staphylococcal infections, treatment of <i>Mycobacterium avium</i> complex infections, treatment of leprosy, treatment of peritonitis, exit site, and tunnel infections in patients with peritoneal dialysis catheters, and eradication of chronic group A <i>Streptococcus</i> carriage.</p></div>
<div class="block mst drugH1Div" id="F218247"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rifadin may be confused with Rifater, Ritalin</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RifAMPin may be confused with ribavirin, rifabutin, Rifamate, rifapentine, rifAXIMin </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F218233"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> OATP1B1/1B3 (SLCO1B1/1B3); <b>Induces</b> BCRP/ABCG2, CYP1A2 (weak), CYP2B6 (moderate), CYP2C19 (strong), CYP2C8 (moderate), CYP2C9 (moderate), CYP3A4 (strong), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1, UGT1A1, UGT1A9</p></div>
<div class="block dri drugH1Div" id="F218151"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abiraterone Acetate.  Management: Avoid when possible. If the combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during combined use. Reduce abiraterone dose back to the prior dose and frequency once strong inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: CYP2C19 Inducers (Strong) may decrease the serum concentration of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Acalabrutinib.  Management: Avoid co-administration of strong CYP3A inducers in patients taking acalabrutinib. If strong CYP3A inducers cannot be avoided, increase the dose of acalabrutinib to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: RifAMPin may enhance the hepatotoxic effect of Acetaminophen. RifAMPin may decrease the serum concentration of Acetaminophen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Adagrasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.  Management: Increase the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-gp inducers with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of the P-gp inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agomelatine: RifAMPin may decrease the serum concentration of Agomelatine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfacalcidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alfacalcidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and strong CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alpelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Amiodarone. CYP3A4 Inducers (Strong) may decrease the serum concentration of Amiodarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline: RifAMPin may decrease serum concentrations of the active metabolite(s) of Amitriptyline. Specifically, concentrations of nortriptyline may be reduced. RifAMPin may decrease the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: CYP2C8 Inducers (Moderate) may decrease the serum concentration of Amodiaquine.  Management: Monitor for reduced amodiaquine efficacy if combined with moderate CYP2C8 inducers. Consider increasing artensunate/amodiaquine treatment duration to 5 days if coadministration with enzyme inducing drugs is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Strong) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Apixaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of ARIPiprazole.  Management: For indications other than major depressive disorder: double the oral aripiprazole dose over 1 to 2 weeks and closely monitor. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Patients taking the 441 mg dose of aripiprazole lauroxil increase their dose to 662 mg if used with a strong CYP3A4 inducer for more than 14 days. No dose adjustment is necessary for patients using the higher doses of aripiprazole lauroxil.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artesunate: RifAMPin may decrease serum concentrations of the active metabolite(s) of Artesunate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: RifAMPin may decrease the serum concentration of Asunaprevir. This effect is most likely with longer-term coadministration; single-dose rifampin may increase asunaprevir concentrations. RifAMPin may increase the serum concentration of Asunaprevir. This effect is likely following only single-dose or short-term rifampin administration.  Longer-term coadministration is likely to result in decreased asunaprevir concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ataluren: RifAMPin may decrease the serum concentration of Ataluren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: RifAMPin may decrease the serum concentration of Atazanavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: RifAMPin may decrease the serum concentration of Atogepant. Specifically, atogepant concentrations may be reduced with daily dosing of rifampin. RifAMPin may increase the serum concentration of Atogepant. Specifically, increases in atogepant exposure may occur with single dose of rifampin or at the initiation of rifampin therapy.  Management: Episodic migraine: atogepant dose should be 10 mg or 30 mg once daily with single dose rifampin, or 30 mg or 60 mg once daily with daily rifampin. Chronic migraine: avoid atogepant with daily rifampin; with single dose rifampin, use atogepant 30 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: RifAMPin may increase the serum concentration of Atorvastatin. RifAMPin may decrease the serum concentration of Atorvastatin.  Management: Administer atorvastatin and rifampin simultaneously if using both. Monitor atorvastatin response closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atovaquone: May increase the serum concentration of RifAMPin. RifAMPin may decrease the serum concentration of Atovaquone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avatrombopag: RifAMPin may decrease the serum concentration of Avatrombopag.  Management: For chronic immune thrombocytopenia, increase initial avatrombopag dose to 40 mg daily. No dosage adjustment needed for patients with chronic liver disease-associated thrombocytopenia using altrombopag prior to a procedure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bazedoxifene: RifAMPin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Berotralstat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Betamethasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bexagliflozin: UGT1A9 Inducers may decrease the serum concentration of Bexagliflozin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: RifAMPin may decrease the serum concentration of Bictegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisoprolol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bisoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosentan: RifAMPin may decrease the serum concentration of Bosentan. Following the initial week of concurrent rifampin, this effect is most likely. RifAMPin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few days of concurrent therapy (and may be greatest immediately following initiation of the combination). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brexpiprazole.  Management: If brexpiprazole is used together with a strong CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks. Decrease brexpiprazole to original dose over 1 to 2 weeks if the strong CYP3A4 inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Brincidofovir.  Management: Consider alternatives to OATP1B/1B3 inhibitors in patients treated with brincidofovir. If coadministration is required, administer OATP1B1/1B3 inhibitors at least 3 hours after brincidofovir and increase monitoring for brincidofovir adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: CYP2C19 Inducers (Strong) may decrease the serum concentration of Brivaracetam.  Management: Increase the brivaracetam dose by up to 100% (ie, double the dose) if used with rifampin and consider the same dose adjustment if used with other strong CYP2C19 inducers. Monitor for reduced brivaracetam efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromocriptine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brotizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brotizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inducers (Moderate) may decrease the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Strong) may decrease the serum concentration of BusPIRone.  Management: Consider alternatives to this combination. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Butorphanol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Butorphanol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabazitaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabazitaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: UGT1A1 Inducers may decrease the serum concentration of Cabotegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.  Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, increase cabozantinib capsules (Cometriq) by 40 mg from previous dose, max 180 mg daily. Increase cabozantinib tablets (Cabometyx) by 20 mg from previous dose, max 80 mg daily<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcifediol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canagliflozin: RifAMPin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: CYP2C19 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Cannabidiol. CYP2C19 Inducers (Strong) may decrease the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carisoprodol: CYP2C19 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Carisoprodol. CYP2C19 Inducers (Strong) may decrease the serum concentration of Carisoprodol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: RifAMPin may decrease the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caspofungin: RifAMPin may decrease the serum concentration of Caspofungin.  Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CeFAZolin: May enhance the adverse/toxic effect of RifAMPin. Specifically, the risk for bleeding may be increased. Management: Avoid concomitant use of rifampin with cefazolin when possible. If combined, closely monitor prothrombin time or other coagulation tests and administer vitamin K as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celecoxib: CYP2C9 Inducers (Moderate) may decrease the serum concentration of Celecoxib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalosporins (N-methylthiotetrazole [NMTT] Side Chain Containing): May enhance the adverse/toxic effect of RifAMPin. Specifically, the risk for bleeding may be increased. Management: Avoid concomitant use of rifampin with cephalosporins that contain an N-methylthiotetrazole (NMTT) side chain when possible. If combined, closely monitor prothrombin time or other coagulation tests and administer vitamin K as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Charcoal, Activated: May decrease the absorption of RifAMPin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): RifAMPin may increase the metabolism of Chloramphenicol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproPAMIDE: CYP3A4 Inducers (Strong) may decrease the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cilnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Citalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: BCRP/ABCG2 Inducers may decrease the serum concentration of Cladribine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Cladribine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and may impair clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClonazePAM: CYP3A4 Inducers (Strong) may decrease the serum concentration of ClonazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: CYP2C19 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Consider alternatives to this combination when possible. If combined, monitor for increased clopidogrel effects and toxicities (eg, bleeding) if clopidogrel is combined with a strong CYP2C19 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine.  Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Clozapine dose reduction and further monitoring may be required when strong CYP3A4 inducers are discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: RifAMPin may decrease the serum concentration of Cobicistat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Copanlisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: CYP2B6 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of CycloPHOSphamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Monitor closely for reduced cyclosporine concentrations when combined with strong CYP3A4 inducers. Cyclosporine dose increases will likely be required to maintain adequate serum concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cyproterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with P-glycoprotein inducers whenever possible.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daclatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daprodustat: CYP2C8 Inducers (Moderate) may decrease the serum concentration of Daprodustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): May enhance the adverse/toxic effect of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Darolutamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: RifAMPin may decrease the serum concentration of Darunavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid concurrent use of dasatinib with strong CYP3A4 inducers when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: UGT1A1 Inducers may decrease the serum concentration of Deferasirox.  Management: Avoid concomitant use of deferasirox and UGT1A1 inducers when possible. If combined, consider a 50% increase in the initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical response to guide further dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Delamanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: RifAMPin may decrease the serum concentration of Delavirdine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of DexAMETHasone (Systemic).  Management: Consider dexamethasone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced dexamethasone efficacy. Consider avoiding this combination when treating life threatening conditions (ie, multiple myeloma).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexlansoprazole: CYP2C19 Inducers (Strong) may decrease the serum concentration of Dexlansoprazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diamorphine: RifAMPin may decrease serum concentrations of the active metabolite(s) of Diamorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Strong) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diclofenac (Systemic): CYP2C9 Inducers (Moderate) may decrease the serum concentration of Diclofenac (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inducers (Strong) may decrease the serum concentration of DilTIAZem.  Management: Consider alternatives to this combination when possible. If combined, monitor for decreased diltiazem efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: RifAMPin may decrease the serum concentration of Dolutegravir.  Management: Increase dolutegravir to 50 mg twice/day in adults. Increase weight-based dose to twice daily in pediatric patients. Specific recommendations vary for combination products; see interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Domperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Doravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: RifAMPin may decrease the serum concentration of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Duvelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ebastine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: RifAMPin may decrease the serum concentration of Edoxaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: RifAMPin may decrease the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of RifAMPin.  Management: Monitor for reduced response to efavirenz and rifampin. Guidelines suggest no efavirenz dose adjustments are required when combined, while labeling recommends an efavirenz dose increase to 800 mg daily in adults weighing more than 50 kg.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: RifAMPin may increase the serum concentration of Elagolix.  Management: Use of the elagolix 200 mg twice daily dose with rifampin is not recommended. Limit combined use of the elagolix 150 mg once daily dose with rifampin to a maximum of 6 months.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix, Estradiol, and Norethindrone: May increase the serum concentration of RifAMPin. Specifically, rifampin may increase elagolix concentrations and decrease estradiol and norethindrone concentrations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: RifAMPin may increase the serum concentration of Elbasvir and Grazoprevir. RifAMPin may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Eluxadoline.  Management: Decrease the eluxadoline dose to 75 mg twice daily if combined with OATP1B1/1B3 inhibitors and monitor patients for increased eluxadoline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: RifAMPin may decrease the serum concentration of Elvitegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Encorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enfortumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Enzalutamide. CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.  Management: Consider using an alternative agent that has no or minimal CYP3A4 induction potential when possible. If this combination cannot be avoided, increase the dose of enzalutamide from 160 mg daily to 240 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eravacycline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eravacycline.  Management: Increase the eravacycline dose to 1.5 mg/kg every 12 hours when combined with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erdafitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.  Management: Avoid the combination of erlotinib and strong CYP3A4 inducers whenever possible. If this combination must be used, increase erlotinib dose by 50 mg increments every 2 weeks as tolerated, to a maximum of 450 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esomeprazole: CYP2C19 Inducers (Strong) may decrease the serum concentration of Esomeprazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethosuximide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide. If combined, monitor patients closely for diminished etoposide response and need for etoposide dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide Phosphate.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide phosphate. If these combinations cannot be avoided, monitor patients closely for diminished etoposide phosphate response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoricoxib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoricoxib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: RifAMPin may decrease the serum concentration of Etrasimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Everolimus.  Management: Afinitor: Double the everolimus daily dose, using increments of 5 mg or less, with careful monitoring; multiple increments may be necessary. Zortress: Avoid if possible and monitor for decreased everolimus concentrations if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Evogliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Increase the exemestane dose to 50 mg once daily in patients receiving concurrent strong CYP3A4 inducers. Monitor patients closely for evidence of toxicity or inadequate clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Felbamate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Felodipine.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced felodipine efficacy and the need for felodipine dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: RifAMPin may decrease the serum concentration of Fenfluramine.  Management: Avoid concurrent use of rifampin with fenfluramine when possible. If combined use cannot be avoided, consider increasing the fenfluramine dose, but do not exceed the fenfluramine maximum daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexofenadine: RifAMPin may decrease the serum concentration of Fexofenadine. RifAMPin may increase the serum concentration of Fexofenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fimasartan: RifAMPin may increase the serum concentration of Fimasartan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: RifAMPin may decrease the serum concentration of Fluconazole. Fluconazole may increase the serum concentration of RifAMPin.  Management: Consider increasing the dose of fluconazole when used concurrently with rifampin. When combined, monitor for both reduced clinical efficacy of fluconazole and increased rifampin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluvastatin: RifAMPin may decrease the serum concentration of Fluvastatin. Specifically, this occurs with prolonged coadministration. RifAMPin may increase the serum concentration of Fluvastatin. Specifically, this occurs upon rifampin initiation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: RifAMPin may decrease the serum concentration of Fosamprenavir. Specifically, concentrations of amprenavir (active metabolite) may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inducers (Strong) may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostemsavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fruquintinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Futibatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and strong CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse reactions, increase the gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume 250 mg dose 7 days after discontinuation of the strong inducer. Carefully monitor clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Gemigliptin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gepirone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gestrinone: RifAMPin may decrease the serum concentration of Gestrinone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Gilteritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Glasdegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: RifAMPin may decrease the serum concentration of Glecaprevir and Pibrentasvir. RifAMPin may increase the serum concentration of Glecaprevir and Pibrentasvir. Specifically, a single dose of rifampin may increase glecaprevir/pibrentasvir concentrations, while chronic daily use of rifampin may decrease glecaprevir/pibrentasvir concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halothane: May enhance the hepatotoxic effect of RifAMPin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a strong CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: RifAMPin may diminish the therapeutic effect of Hydroxychloroquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Idelalisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid use of imatinib and strong CYP3A4 inducers when possible. If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely. Doses up to 1200 mg/day (600 mg twice daily) have been used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: RifAMPin may decrease the serum concentration of Indinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iptacopan: CYP2C8 Inducers (Moderate) may decrease the serum concentration of Iptacopan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products.  Management: Avoid administration of strong CYP3A4 inducers during irinotecan treatment, and substitute non-CYP3A4 inducing agents at least 2 weeks prior to irinotecan initiation, whenever possible. If combined, monitor for reduced irinotecan efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May enhance the hepatotoxic effect of RifAMPin. RifAMPin may decrease the serum concentration of Isoniazid.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Istradefylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivosidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible. If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixazomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketoconazole (Systemic).  Management: The use of ketoconazole concurrently with or within 2 weeks of a strong CYP3A4 inducer is not recommended. If such a combination cannot be avoided, monitor patients closely for evidence of diminished clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lacidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: RifAMPin may decrease the serum concentration of LamoTRIgine.  Management: For patients taking rifampin without valproate, lamotrigine dose adjustments are recommended for lamotrigine initiation. Recommendations vary based on lamotrigine indication and age. See full interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lansoprazole: CYP2C19 Inducers (Strong) may decrease the serum concentration of Lansoprazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If concomitant use cannot be avoided, titrate lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Larotrectinib.  Management: Avoid use of strong CYP3A4 inducers with larotrectinib. If this combination cannot be avoided, double the larotrectinib dose. Reduced to previous dose after stopping the inducer after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin intravenous infusion with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: RifAMPin may increase serum concentrations of the active metabolite(s) of Leflunomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: UGT1A1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leuprolide and Norethindrone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leuprolide and Norethindrone. Specifically, norethindrone concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonorgestrel (IUD): CYP3A4 Inducers (Strong) may diminish the therapeutic effect of Levonorgestrel (IUD). CYP3A4 Inducers (Strong) may decrease the serum concentration of Levonorgestrel (IUD). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Strong) may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: RifAMPin may enhance the adverse/toxic effect of Lopinavir. Specifically, the risk of hepatocellular toxicity may be increased. RifAMPin may decrease the serum concentration of Lopinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Strong) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Lorlatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lornoxicam: CYP2C9 Inducers (Moderate) may decrease the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumacaftor and Ivacaftor. Specifically, the serum concentration of ivacaftor may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurbinectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inducers. If combined, monitor closely for decreased manidipine effects and loss of efficacy. Increased manidipine doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maribavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mefloquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylergonovine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Methylergonovine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: RifAMPin may decrease the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: RifAMPin may decrease the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mianserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midostaurin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirodenafil.  Management: Consider avoiding the concomitant use of mirodenafil and strong CYP3A4 inducers. If combined, monitor for decreased mirodenafil effects. Mirodenafil dose increases may be required to achieve desired effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirtazapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mitapivat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Momelotinib: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Momelotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): RifAMPin may decrease the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): RifAMPin may decrease the serum concentration of Moxifloxacin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: RifAMPin may decrease serum concentrations of the active metabolite(s) of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be decreased.  Management: Avoid concurrent use of rifampin and mycophenolate when possible. If used together, closely monitor mycophenolic acid levels and clinical response. Mycophenolate doses may need to be increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naldemedine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nateglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nateglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: RifAMPin may decrease the serum concentration of Nelfinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Netupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: RifAMPin may decrease the serum concentration of Nevirapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiCARdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiCARdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Avoid coadministration of nifedipine with strong CYP3A4 inducers when possible and if combined, monitor patients closely for clinical signs of diminished nifedipine response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Nintedanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nirmatrelvir and Ritonavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrazepam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nortriptyline: RifAMPin may decrease the serum concentration of Nortriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: RifAMPin may decrease the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: CYP2C19 Inducers (Strong) may decrease the serum concentration of Omeprazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ondansetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: RifAMPin may decrease the serum concentration of Ornidazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osilodrostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib.  Management: Avoid coadministration of osimertinib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase osimertinib to 160 mg daily. Reduce osimertinib to 80 mg daily 3 weeks after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: RifAMPin may decrease the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: CYP3A4 Inducers (Strong) may decrease the serum concentration of OXcarbazepine. Specifically, the concentrations of the 10-monohydroxy active metabolite of oxcarbazepine may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: CYP2C8 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ozanimod. CYP2C8 Inducers (Moderate) may decrease the serum concentration of Ozanimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Paliperidone.  Management: Monitor for reduced paliperidone effects when combined with strong inducers of both CYP3A4 and P-gp. Avoid use of these inducers with extended-release injectable paliperidone and instead manage patients with paliperidone extended-release tablets.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pefloxacin: RifAMPin may decrease the serum concentration of Pefloxacin. Pefloxacin may increase the serum concentration of RifAMPin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used  with strong CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pexidartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: CYP2C8 Inducers (Moderate) may decrease the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pirtobrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitavastatin: RifAMPin may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pitolisant.  Management: If on a stable pitolisant dose of 8.9 mg or 17.8 mg/day and starting a strong CYP3A4 inducer, double the pitolisant dose over 7 days (ie, to either 17.8 mg/day or 35.6 mg/day, respectively). Reduce pitolisant dose by 50% when the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polatuzumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.  Management: Avoid coadministration of ponatinib with strong CYP3A4 inducers unless the potential benefit of concomitant treatment outweighs the risk of reduced ponatinib exposure. Monitor patients for reduced ponatinib efficacy if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: UGT1A1 Inducers may decrease the serum concentration of Ponesimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: RifAMPin may decrease the serum concentration of Posaconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pralsetinib.  Management: Avoid concomitant use of pralsetinib with strong CYP3A4 inducers when possible. If combined, increase the starting dose of pralsetinib to double the current pralsetinib dosage starting on day 7 of coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pravastatin: RifAMPin may decrease the serum concentration of Pravastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of RifAMPin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: RifAMPin may enhance the hepatotoxic effect of Propacetamol. RifAMPin may increase the metabolism of Propacetamol. . This may 1) diminish the desired effects of propacetamol; and 2) increase the risk of liver damage. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: RifAMPin may enhance the hypotensive effect of Propofol.  Management: Avoid this combination if possible. Use of propofol in a patient who has been taking rifampin may result in clinically significant hypotension.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: RifAMPin may decrease the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: RifAMPin may enhance the hepatotoxic effect of Prothionamide.  Management: Avoid concomitant use of prothionamide and rifampin if possible. If combined use is considered necessary, monitor patients closely for signs and symptoms of hepatotoxicity (eg, jaundice, elevations in liver function tests).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyrazinamide: May enhance the hepatotoxic effect of RifAMPin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection. Management: Rifampin-pyrazinamide is generally not preferred for the treatment of latent tuberculosis (TB) due to the risk of hepatotoxicity. However, it is an option for patients at high risk of developing active TB who are unlikely to complete preferred treatment.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.  Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7 to 14 days of discontinuing the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: RifAMPin may decrease the serum concentration of QuiNINE. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Radotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Radotinib.  Management: Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: RifAMPin may decrease the serum concentration of Raltegravir.  Management: Increase raltegravir dose to 800 mg twice daily (adult dose) when used concomitantly with rifampin. Concurrent use of rifampin with once-daily raltegravir (Isentress HD) is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Reboxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: RifAMPin may decrease the serum concentration of Red Yeast Rice. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Relugolix.  Management: Avoid use of relugolix with drugs that are both strong CYP3A4 and  P-glycoprotein (P-gp) inducer. If combined, increase the dose of relugolix to 240 mg once daily. Reduce back to 120 mg daily once the combined inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Relugolix, Estradiol, and Norethindrone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: RifAMPin may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase serum concentrations of the active metabolite(s) of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: RifAMPin may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ripretinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Strong) may decrease the serum concentration of RisperiDONE.  Management: Careful monitoring for reduced risperidone efficacy and possible dose adjustment are recommended when combined with strong CYP3A4 inducers. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: RifAMPin may decrease the serum concentration of Ritonavir. RifAMPin may increase the serum concentration of Ritonavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Rivaroxaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rolapitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: RifAMPin may increase the serum concentration of RomiDEPsin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: CYP2C8 Inducers (Moderate) may decrease the serum concentration of Rosiglitazone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: RifAMPin may decrease the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: CYP2C8 Inducers (Moderate) may decrease the serum concentration of Roxadustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ruxolitinib (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab Govitecan: UGT1A1 Inducers may decrease serum concentrations of the active metabolite(s) of Sacituzumab Govitecan. Specifically, concentrations of SN-38 may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Samidorphan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: RifAMPin may enhance the adverse/toxic effect of Saquinavir. Specifically, the risk of hepatocellular toxicity may be increased. RifAMPin may decrease the serum concentration of Saquinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selexipag: RifAMPin may decrease serum concentrations of the active metabolite(s) of Selexipag.  Management: Increase the selexipag dose (up to 2-fold) when combined with rifampin. Monitor for decreased selexipag efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: RifAMPin may decrease the serum concentration of Siponimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Conventional).  Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotagliflozin: UGT1A9 Inducers may decrease the serum concentration of Sotagliflozin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stiripentol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Stiripentol.  Management: Avoid concomitant use of stiripentol and strong CYP3A4 inducers when possible. If combined, monitor for reduced stiripentol efficacy and increase the stiripentol dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inducer is initiated in a patient on sufentanil, consider a sufentanil dose increase and monitor for decreased sufentanil effects and opioid withdrawal symptoms.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfamethoxazole: RifAMPin may decrease the serum concentration of Sulfamethoxazole. Sulfamethoxazole may increase the serum concentration of RifAMPin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: CYP2C9 Inducers (Moderate) may decrease the serum concentration of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If combined, increase sunitinib dose to a max of 87.5 mg daily when treating GIST or RCC. Increase sunitinib dose to a max of 62.5 mg daily when treating PNET. Monitor patients for both reduced efficacy and increased toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Tacrolimus (Systemic).  Management: Monitor for decreased tacrolimus concentrations and effects when combined with strong CYP3A4 inducers. Tacrolimus dose increases will likely be needed during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction or benign prostatic hypertrophy: monitor for decreased effectiveness - no standard dose adjustment is recommended. Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tasimelteon. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Taurursodiol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Temsirolimus.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inducers. If coadministration is unavoidable, increase temsirolimus dose to 50 mg per week. Resume previous temsirolimus dose after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Alafenamide: RifAMPin may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terbinafine (Systemic): RifAMPin may decrease the serum concentration of Terbinafine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertatolol: RifAMPin may decrease the serum concentration of Tertatolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol.  Management: Avoid use of the tetrahydrocannabinol/cannabidiol oromucosal spray and strong CYP3A4 inducers when possible. If combined use is necessary, careful titration is recommended, notably within the two weeks following discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: RifAMPin may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Strong) may decrease the serum concentration of Thiotepa.  Management: Thiotepa prescribing information recommends avoiding concomitant use of thiotepa and strong CYP3A4 inducers. If concomitant use is unavoidable, monitor for adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: RifAMPin may decrease the serum concentration of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiaGABine: CYP3A4 Inducers (Strong) may decrease the serum concentration of TiaGABine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: RifAMPin may decrease the serum concentration of Tipranavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tivozanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Torsemide: CYP2C9 Inducers (Moderate) may decrease the serum concentration of Torsemide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Strong) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inducers (Strong) may decrease the serum concentration of TraZODone.  Management: Consider increasing the trazodone dose during coadministration with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Triamcinolone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Triazolam.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced triazolam efficacy. Substantial triazolam dose increases will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: RifAMPin may decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of RifAMPin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tropisetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tropisetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP2C8 Inducers (Moderate) may decrease the serum concentration of Tucatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ubrogepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: RifAMPin may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP2B6 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.  Management: Avoid coadministration of vemurafenib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase the vemurafenib dose by 240 mg as tolerated. Resume prior vemurafenib dose 2 weeks after discontinuation of strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Strong) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Verapamil.  Management: Consider alternatives to this combination. If combined, monitor for reduced verapamil efficacy. Verapamil dose increases may be necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.  Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients receiving strong CYP3A4 inducers for &gt; 14 days. Reduce to the original vilazodone dose over 1 to 2 weeks after inducer discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinorelbine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinorelbine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Rifamycin Derivatives may decrease the serum concentration of Vitamin K Antagonists.  Management: Consider alternatives if possible. If combined, monitor for reduced anticoagulant effects if a rifamycin derivative is initiated in a vitamin K antagonist treated patient. Vitamin K antagonist dose adjustments will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: RifAMPin may decrease the serum concentration of Voriconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vortioxetine.  Management: Consider increasing the vortioxetine dose to no more than 3 times the original dose when used with a strong drug metabolism inducer for more than 14 days. The vortioxetine dose should be returned to normal within 14 days of stopping the strong inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and strong CYP3A4 inducers. If  unavoidable, increase the voxelotor dose to 2,500 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: RifAMPin may increase the serum concentration of Voxilaprevir. Specifically, a single dose of rifampin may increase voxilaprevir concentrations, while chronic daily use of rifampin may decrease voxilaprevir concentrations. RifAMPin may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zaleplon.  Management: Consider the use of an alternative hypnotic that is not metabolized by CYP3A4 in patients receiving strong CYP3A4 inducers. If zaleplon is combined with a strong CYP3A4 inducer, monitor for decreased effectiveness of zaleplon.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zanubrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors may increase the serum concentration of Zavegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: RifAMPin may decrease the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ziprasidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zonisamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zonisamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F218183"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food decreases the extent of absorption; rifampin concentrations may be decreased if taken with food. Management: Administer on an empty stomach with a glass of water (ie, 1 hour prior to, or 2 hours after meals or antacids). </p></div>
<div class="block rep_considerations drugH1Div" id="F54928137"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Rifampin may decrease the effectiveness of hormonal contraceptives. Consult drug interactions database for more detailed information specific to use of rifampin and specific contraceptives.</p></div>
<div class="block pri drugH1Div" id="F218169"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Rifampin crosses the human placenta. Postnatal hemorrhages have been reported in the infant and mother with administration during the last few weeks of pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Rifampin is approved for the treatment of tuberculosis (TB). TB disease (active TB) is associated with adverse fetal outcomes, including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020), as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020). Due to the risks of untreated TB, rifampin is recommended as part of the initial treatment regimen of drug-susceptible TB disease when the probability of maternal disease is moderate to high (ATS/CDC/IDSA [Nahid 2016]). Rifampin may also be considered for the treatment of TB infection (latent TB) (also known as prophylaxis or preventive therapy) in pregnant patients (WHO 2020). Rifampin may be associated with an increased risk of maternal hepatotoxicity, which may require temporary drug withdrawal in pregnant and postpartum patients (Beck-Friis 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Rifampin is used off-label for the treatment of brucellosis infection. Brucellosis infection may increase the risk of spontaneous abortion; rifampin is recommended for the treatment of brucellosis infection during pregnancy (CDC 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Rifampin may be considered for use as an alternative agent in pregnant patients for the treatment of mild illness due to human anaplasmosis (also known as human granulocytic anaplasmosis); case reports have shown favorable maternal and pregnancy outcomes in small numbers of rifampin-treated pregnant women (CDC [Biggs 2016]).</p></div>
<div class="block mopp drugH1Div" id="F53568687"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Liver function (AST, ALT, bilirubin); monitor every 2 to 4 weeks in patients with impaired liver function at baseline. CBC, SCr (CFF/ECFS [Floto 2016]; manufacturer's labeling). Monitor coagulation tests during treatment in patients at risk of vitamin K deficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">Leprosy (Hansen Disease): CBC with platelets and comprehensive metabolic panel every 3 months (NHDP/HRSA 2018).</p></div>
<div class="block rerp drugH1Div" id="F55599389"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Tuberculosis treatment:</p>
<p style="text-indent:-2em;margin-left:4em;">Target peak: ≥8 mg/L; often obtained at 2 hours postdose (Alsultan 2014; Aruldhas 2019; Chigutsa 2015; Hiruy 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> AUC<sub>24</sub> has also been suggested as a target pharmacodynamic parameter, though value associated with efficacy has varied (≥13 to 35 mg•hr/L) (Chigutsa 2015; Hiruy 2015; Pasipanodya 2013).</p></div>
<div class="block pha drugH1Div" id="F218145"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial RNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase, blocking RNA transcription</p></div>
<div class="block phk drugH1Div" id="F218165"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: ≤24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed; food may delay or slightly reduce peak.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Highly lipophilic; crosses blood-brain barrier well.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: Neonates, Infants, Children, and Adolescents: ~1.1 L/kg (Nahata 1990; Smith 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Relative diffusion from blood into CSF: Adequate with or without inflammation (exceeds usual MICs).</p>
<p style="text-indent:-2em;margin-left:4em;">CSF:blood level ratio: Inflamed meninges: 25%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 80%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; undergoes enterohepatic recirculation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and Infants &lt;4 months (GA ≥23 weeks): PNA &lt;14 days: Median: 7.1 hours (range: 3 to 23.9 hours); PNA ≥14 days: Median: 3.5 hours (range: 1.9 to 6.5 hours) (Smith 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥4 months and Children: ~1 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~2 to 3 hours (steady-state).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children 6 months to &lt;5 years: Oral: 1 hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oral: ~2 hours (Acocella 1978).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (60% to 65%) and urine (≤30%) as unchanged drug.</p></div>
<div class="block phksp drugH1Div" id="F56321250"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Altered kidney function: Half-life prolonged from 3.6 hours (GFR &gt;50 mL/minute) to 5 hours (GFR 30 to 50 mL/minute), 7.3 hours (GFR &lt;30 mL/minute) and 11 hours (patients who are anuric) following a single 900 mg dose. No increase in half-life has been observed with doses ≤600 mg/day.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F218171"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Archidyn | Rifadin | Rimactane | Rimpacin | Tibirim</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Rifadecina | Rifadin | Rifalep | Rifampicina Kilab | Rifampicina richet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eremfat | Rifoldin | Rimactan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rimycin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Firifam | G-rifampicin | Ifampin | Mycin | Refambin | Refanin | Rifacin | Rifajap | Rifampin | Rifanol | Rifatan | Rifcin | Rimactane</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rifadine | Rimactan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tubocin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Furp rifampicina | Monicil | Rifaldin | Rifamp | Rifampicina | Rifondil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Rifampicin Labatec | Rifampicine | Rifampicine labatec | Rimactan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rifaldin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Benemicin | Rifampicin capsules (ii) | Rifampicin co | Rifandin | Rifandine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifampicina | Rifampicina mk | Rimactan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Arficin | Benemycin | Eremfat | Rifadin | Rifamor | Tubocin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Eremfat | Rifa | RifampicinHefa-N | Rifoldin | Rimactan</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Rimactan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Rifampicina | Rifapen | Rimactan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Rifadex | Rifampicina | Rifampicina mk | Rimactan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Eremfat | Eremfat i.v. | Rifadin | Rifasynt | Rifcap | Rimactane | Sinerdol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Rifactine | Rifadin | Rifam | Rifampin | Rimactane</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Rifaldin | Rimactan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rifacur | Rifarm | Rimactan | Rimapen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rifadine | Rimactan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifampicin kent | Rimactane</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifadine/Aventis Pharma | Rifampicyna tzf</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Rif | Rifacin | Rifadin | Rifamina | Rifasynt | Rificin | Yuan chou rifampicin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Arficin | Rimactan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tubocin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Corifam | Decarifam | Famri | Kalrifam | Lanarif | Medirif | Megarif | Pulmofam | Ramicin | Rarifam | Rif | Rifabiotic | Rifacin | Rifam | Rifamec | Rifampin | Rifamtibi | Rimacen | Rimactane | Rimafin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rimactane</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Rimactan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acirimpi | Famicox | Gocox | Ls-Rif | Macox | Montomycin | Osorifa | R cin | Refazole | Rf | Rifacept | Rifacon | Rifalife | Rifalin | Rifalite | Rifaminal | Rifasain | Rimactane | Rimpacin | Rimpin | Ripim | Ticin | Tubercin | Zucox</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifapiam</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifasynt</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aptecin | Rifadin | Rifampicin amel | Rifampicin chemiphar | Rifampicin hexal | Rifampicin merck hoei | Rifampicin nipro | Rifampicin organon | Rifampicin sawai | Rifampicin tsuruhara | Rimactane | Rivrion</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Laefacin | Macox | Rifacos | Unirif</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hanlim rifampicin | Rifadin | Rifampin | Rifodex | Rimactane</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Rifadin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Rifadin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Benemicin | Eremfat | Rifadin | Rifamor | Rifampicin belmed | Rimactan | Tubocin | Tuborin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rifadine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Benemicin | Eremfat | Rifa | Rifadin | Rifamor | Rimactan | Tubocin | Tuborin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Rifacine | Rifadine | Rimactan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Eurifam | Finamicina | Rifadin | Rifampicina | Rifawest | Rimactan | Rimfir</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Rifacap | Rifadin | Rifam | Rifampin | Rifasynt | Siticox</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Beorifam | Chez rifampicin | Kinglion rifampicin | Rifamax | Rifanise</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifampicine | Rimactan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eremfat | Eremfat farma mondo | Rifa | Rifadin | Rimactan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Rifadin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Rifampicina | Rimactan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Boie rifampicin | Crisarfam | Dipicin | Dli-rifampicin | Eufropin | F.A.R | Famidex | Fampisec | Flemodam | Framacin | Lafayette rifampicin | Medifam | Mgl-rifampicin | Natricin | Odifam | Picinaf | Pyloram | Ramicin | Refam | Resimin | Rexilan | Rifadin | Rifarama | Rimactane | Riprocin | Tubercox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Remedil | Rifadin | Rifamp | Rifapin | Rifocin | Rimacin | Rimactal</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Eremfat | Rifadin | Rifadine | Rifampicin Hefa N | Rifogal | Rifoldin | Rimactan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifampin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Rifadex | Rifadin | Rifampicina | Rifex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Oxitrin | Rifadin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Rifadin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Rifamor | Rifampicina | Rifampicina arena | Sinerdol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Benemicin | Eremfat | Macox | R cin | Rifacin | Rifamor | Rifampicin binergia | Rifampicin deco | Rifampicin ferein | Rifampicin-deko | Rifaren | Rimactan | Rimpacin | Rimpin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Rifacin | Rifadin | Rifasynt | Rifcap</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifampicin abboxia | Rifampicin ebb | Rimactan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Rifaren | Rimactane | Rimycin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Arficin | Benemicin | Eremfat | Rifadin | Rifadine | Rifampicyna tzf | Rifasynt | Rimactan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Arficin | Benemicin | Rifasynt | Tubocin</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Unirif</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Manorifcin | Ramfin | Ricin | Rifa | Rifacin-A | Rifadin | Rifagen | Rifam | Rifamcin | Rifampixyl | Rifasynt | Rifawin | Rifodex | Rifold | Rigocin | Rimaccin | Rimactane | Rimecin | Ripin | Rofacin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Rifadine | Rifampicine | Sinerdol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifcap</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Rifa | Rifadin | Rifamcin | Rifamnicin | Rifampin | Rifamtibi | Rimactane | Rimancin | Ripin | Ripolin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Benemicin | Coxcide | Macox | R cin | Rifampin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rimactan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rifadin | Rifampicina | Rimactan</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agifamcin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Eremfat | R cin | Rimactane | Rolab-rifampicin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Rifa</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Rifacure | Stririfa 150</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-346286">
<a name="346286"></a>Acocella G. Clinical Pharmacokinetics of Rifampicin. <i>Clin Pharmacokinet</i>. 1978;3(2):108-127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/346286/pubmed" id="346286" target="_blank">346286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6845400">
<a name="6845400"></a>Advenier C, Gobert C, Houin G, et al. Pharmacokinetic Studies of Rifampicin in the Elderly. <i>Ther Drug Monit</i>. 1983;5(1):61-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/6845400/pubmed" id="6845400" target="_blank">6845400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12968844">
<a name="12968844"></a>Ahn C, Oh KH, Kim K, et al. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin. <i>Perit Dial Int</i>. 2003;23(4):362-367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/12968844/pubmed" id="12968844" target="_blank">12968844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30872149">
<a name="30872149"></a>Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. <i>J Am Acad Dermatol</i>. 2019;81(1):91‐101. doi:10.1016/j.jaad.2019.02.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30872149/pubmed" id="30872149" target="_blank">30872149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29274824">
<a name="29274824"></a>Allouchery M, Logerot S, Cottin J, Pralong P, Villier C, Ben Saïd B; French Pharmacovigilance Centers Network and the French Investigators for skin adverse reactions to drugs. Antituberculosis drug-associated DRESS: A case series. <i>J Allergy Clin Immunol Pract</i>. 2018;6(4):1373-1380. doi:10.1016/j.jaip.2017.11.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/29274824/pubmed" id="29274824" target="_blank">29274824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18539496">
<a name="18539496"></a>Alp E, Doganay M. Current therapeutic strategy in spinal brucellosis. <i>Int J Infect Dis</i>. 2008;12(6):573‐577. doi:10.1016/j.ijid.2008.03.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/18539496/pubmed" id="18539496" target="_blank">18539496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24846578">
<a name="24846578"></a>Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. <i>Drugs</i>. 2014; 74:839.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/24846578/pubmed" id="24846578" target="_blank">24846578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Kimberlin DW, Brady MT, Jackson MA, Long SA, eds; Committee on Infectious Diseases; American Academy of Pediatrics. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. American Academy of Pediatrics; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1728006">
<a name="1728006"></a>American Academy of Pediatrics Committee on Infectious Diseases. Chemotherapy for Tuberculosis in Infants and Children. <i>Pediatrics</i>. 1992;89(1):161-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/1728006/pubmed" id="1728006" target="_blank">1728006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.2">
<a name="ASHP.2"></a>American Society of Health-System Pharmacists (ASHP). Compounded oral liquid standards. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Compound-Oral-Liquid.pdf. Updated July 2022. Accessed April 25, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28069912">
<a name="28069912"></a>Andrès E, Mourot-Cottet R, Maloisel F, et al. Idiosyncratic drug-induced neutropenia &amp; agranulocytosis. <i>QJM</i>. 2017;110(5):299-305. doi:10.1093/qjmed/hcw220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/28069912/pubmed" id="28069912" target="_blank">28069912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18162038">
<a name="18162038"></a>Ariza J, Bosilkovski M, Cascio A, et al; International Society of Chemotherapy; Institute of Continuing Medical Education of Ioannina. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. <i>PLoS Med</i>. 2007;4(12):e317. doi:10.1371/journal.pmed.0040317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/18162038/pubmed" id="18162038" target="_blank">18162038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14665784">
<a name="14665784"></a>Ashitani J, Yanagi S, Arimura Y, Sano A, Mukae H. Acute respiratory distress syndrome induced by rifampicin with high levels of neutrophil and eosinophil products in bronchoalveolar lavage fluid. <i>Respiration</i>. 2003;70(5):541-543. doi:10.1159/000074216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/14665784/pubmed" id="14665784" target="_blank">14665784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30588647">
<a name="30588647"></a>Aruldhas BW, Hoglund RM, Ranjalkar J, et al. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. <i>Br J Clin Pharmacol</i>. 2019;85(3):644-654. doi:10.1111/bcp.13846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30588647/pubmed" id="30588647" target="_blank">30588647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7701468">
<a name="7701468"></a>Askgaard DS, Wilcke T, Dossing M. Hepatotoxicity Caused by the Combined Action of Isoniazid and Rifampin. <i>Thorax</i>. 1995;50(2):213-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/7701468/pubmed" id="7701468" target="_blank">7701468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32840240">
<a name="32840240"></a>Ata F, Shaher Mousa Hussein M, Mismar AY, et al. Rifampicin-induced pneumonitis mimicking severe COVID-19 pneumonia infection. <i>Am J Case Rep</i>. 2020;21:e927586. doi:10.12659/AJCR.927586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/32840240/pubmed" id="32840240" target="_blank">32840240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17016895">
<a name="17016895"></a>Ayaslioglu E, Erkek E, Oba AA, Cebecioğlu E. Doxycycline-induced staining of permanent adult dentition. <i>Aust Dent J</i>. 2005;50(4):273-275. doi:10.1111/j.1834-7819.2005.tb00373.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/17016895/pubmed" id="17016895" target="_blank">17016895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16911558">
<a name="16911558"></a>Azad A, Connelly N. Case of rifampicin-induced acute generalized exanthematous pustulosis. <i>Intern Med J</i>. 2006;36(9):619-620. doi:10.1111/j.1445-5994.2006.01163.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/16911558/pubmed" id="16911558" target="_blank">16911558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.1">
<a name="Berbari.1"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour LM, Flynn PM, Fekete T. Infections of cerebrospinal fluid shunts and other devices. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 20, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36043414">
<a name="36043414"></a>Baddour LM, Weimer MB, Wurcel AG, et al; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. Management of infective endocarditis in people who inject drugs: a scientific statement from the American Heart Association. <i>Circulation</i>. 2022a;146(14):e187-e201. doi:10.1161/CIR.0000000000001090.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/36043414/pubmed" id="36043414" target="_blank">36043414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30704698">
<a name="30704698"></a>Ban GY, Jeong YJ, Lee SH, et al. Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications. <i>Respir Med</i>. 2019;147:44-50. doi:10.1016/j.rmed.2018.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30704698/pubmed" id="30704698" target="_blank">30704698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8173779">
<a name="8173779"></a>Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children. <i>Am J Respir Crit Care Med</i>. 1994;149(5):1359-1374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/8173779/pubmed" id="8173779" target="_blank">8173779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32592906">
<a name="32592906"></a>Beck-Friis J, Studahl M, Yilmaz A, Andersson R, Lönnermark E. Increased risk of hepatotoxicity and temporary drug withdrawal during treatment of active tuberculosis in pregnant women. <i>Int J Infect Dis</i>. 2020;98:138-143. doi:10.1016/j.ijid.2020.06.069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/32592906/pubmed" id="32592906" target="_blank">32592906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30142743">
<a name="30142743"></a>Bessaleli E, Scheinfeld N. <i>Clostridium difficile</i> arising in a patient with hidradenitis suppurativa on clindamycin and rifampin. <i>Dermatol Online J</i>. 2018;24(5):13030/qt3x20x5rj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30142743/pubmed" id="30142743" target="_blank">30142743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27172113">
<a name="27172113"></a>Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/27172113/pubmed" id="27172113" target="_blank">27172113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15917737">
<a name="15917737"></a>Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Recomm Rep</i>. 2005;54(RR-7):1‐21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/15917737/pubmed" id="15917737" target="_blank">15917737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1558427">
<a name="1558427"></a>Borcherding SM, Baciewicz AM, Self TH. Update on Rifampin Drug Interactions. II. <i>Arch Intern Med</i>. 1992;152(4):711-716.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/1558427/pubmed" id="1558427" target="_blank">1558427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bosilkovski.1">
<a name="Bosilkovski.1"></a>Bosilkovski M. Brucellosis: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26706674">
<a name="26706674"></a>Bosilkovski M, Krteva L, Caparoska S, Labacevski N, Petrovski M. Childhood brucellosis: review of 317 cases. <i>Asian Pac J Trop Med</i>. 2015;8(12):1027-1032. doi:10.1016/j.apjtm.2015.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/26706674/pubmed" id="26706674" target="_blank">26706674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24572654">
<a name="24572654"></a>Briere EC, Rubin L, Moro PL, et al. Prevention and control of <i>Haemophilus influenzae</i> type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2014;63(RR-01):1-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/24572654/pubmed" id="24572654" target="_blank">24572654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30755272">
<a name="30755272"></a>Brockhaus L, Schmid Y, Rast AC, Rätz Bravo AE, Hofmeier KS, Leuppi-Taegtmeyer AB. Hypersensitivity reaction with multi-organ failure following re-exposure to rifampicin: case report and review of the literature including WHO spontaneous safety reports. <i>BMC Pharmacol Toxicol</i>. 2019;20(1):9. doi:10.1186/s40360-019-0289-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30755272/pubmed" id="30755272" target="_blank">30755272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16514245">
<a name="16514245"></a>Buergin S, Scherer K, Häusermann P, Bircher AJ. Immediate hypersensitivity to rifampicin in 3 patients: diagnostic procedures and induction of clinical tolerance. <i>Int Arch Allergy Immunol</i>. 2006;140(1):20-26. doi:10.1159/000091839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/16514245/pubmed" id="16514245" target="_blank">16514245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2017">
<a name="CDC.2017"></a>Centers for Disease Control and Prevention (CDC). Brucellosis reference guide: exposures, testing, and prevention. <a href="https://www.cdc.gov/brucellosis/pdf/brucellosi-reference-guide.pdf" target="_blank">https://www.cdc.gov/brucellosis/pdf/brucellosi-reference-guide.pdf</a>. Updated February 2017. Accessed March 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). FAQs for Clinicians about <i>C. diff</i>. 2020. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>. Published May 26, 2020. Accessed May 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Latent tuberculosis infection: a guide for primary health care providers. 2013. <a href="https://www.cdc.gov/tb/?404;http://www.cdc.gov:80/tb/publications/ltbi/pdf/TargetedLTBI.pdf" target="_blank">http://www.cdc.gov/tb/?404;http://www.cdc.gov:80/tb/publications/ltbi/pdf/TargetedLTBI.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC). Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - United States, 2003. <i>MMWR</i>, 52(31);735-9. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3919171">
<a name="3919171"></a>Chaudhary S, Bilinsky SA, Hennessy JL, et al. Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy. <i>J Pediatr</i>. 1985;106(3):481-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/3919171/pubmed" id="3919171" target="_blank">3919171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243988">
<a name="24243988"></a>Chien JY, Chien ST, Huang SY, Yu CJ. Safety of rifabutin replacing rifampicin in the treatment of tuberculosis: a single-centre retrospective cohort study. <i>J Antimicrob Chemother</i>. 2014;69(3):790-796. doi:10.1093/jac/dkt446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/24243988/pubmed" id="24243988" target="_blank">24243988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25313213">
<a name="25313213"></a>Chigutsa E, Pasipanodya JG, Visser ME, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. <i>Antimicrob Agents Chemother</i>. 2015;59(1):38-45. doi:10.1128/AAC.03931-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/25313213/pubmed" id="25313213" target="_blank">25313213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23515099">
<a name="23515099"></a>Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2013;62(RR-2):1‐28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/23515099/pubmed" id="23515099" target="_blank">23515099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30083412">
<a name="30083412"></a>Collado-Chagoya R, Hernández-Romero J, Eliosa-Alvarado GA, et al. Tolerance induction to antituberculosis drugs in a patient with stevens-johnson syndrome/toxic epidermal necrolysis overlap. <i>Allergy Rhinol (Providence)</i>. 2018 Aug 1;9:2152656718783618. doi:10.1177/2152656718783618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30083412/pubmed" id="30083412" target="_blank">30083412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corbel.2006">
<a name="Corbel.2006"></a>Corbel MJ; World Health Organization (WHO). Brucellosis in humans and animals. https://www.who.int/csr/resources/publications/Brucellosis.pdf. Published 2006. Accessed May 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31021423">
<a name="31021423"></a>Coster A, Aerts O, Herman A, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome caused by first-line antituberculosis drugs: Two case reports and a review of the literature. <i>Contact Dermatitis</i>. 2019;81(5):325-331. doi:10.1111/cod.13296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/31021423/pubmed" id="31021423" target="_blank">31021423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15195854">
<a name="15195854"></a>Covic A, Golea O, Segall L, et al. A clinical description of rifampicin-induced acute renal failure in 170 consecutive cases. <i>J Indian Med Assoc</i>. 2004;102(1):20, 22-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/15195854/pubmed" id="15195854" target="_blank">15195854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2179027">
<a name="2179027"></a>Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. <i>Gastroenterology</i>. 1990;98(4):1013-1016. doi:10.1016/0016-5085(90)90027-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/2179027/pubmed" id="2179027" target="_blank">2179027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11751562">
<a name="11751562"></a>Daher R, Haidar JH, Al-Amin H. Rifampin Interference With Opiate Immunoassays. <i>Clin Chem</i>. 2002;48(1):203-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/11751562/pubmed" id="11751562" target="_blank">11751562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32797222">
<a name="32797222"></a>Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>Clin Infect Dis</i>. 2020;71(4):905-913. doi:10.1093/cid/ciaa1125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/32797222/pubmed" id="32797222" target="_blank">32797222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1379145">
<a name="1379145"></a>Davidson PT, Le HQ. Drug Treatment of Tuberculosis - 1992. <i>Drugs</i>. 1992;43(5):651-673.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/1379145/pubmed" id="1379145" target="_blank">1379145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27899384">
<a name="27899384"></a>Denny N, Raghunath S, Bhatia P, Abdelaziz M. Rifampicin-induced adrenal crisis in a patient with tuberculosis: a therapeutic challenge. <i>BMJ Case Rep</i>. 2016;2016:bcr2016216302. doi:10.1136/bcr-2016-216302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/27899384/pubmed" id="27899384" target="_blank">27899384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27753139">
<a name="27753139"></a>Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. <i>Clin Exp Dermatol</i>. 2016;41(8):852‐857. doi:10.1111/ced.12933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/27753139/pubmed" id="27753139" target="_blank">27753139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9428460">
<a name="9428460"></a>De Vriese AS, Robbrecht DL, Vanholder RC, et al. Rifampicin-Associated Acute Renal Failure: Pathophysiologic, Immunologic, and Clinical Features. <i>Am J Kidney Dis</i>. 1998;31(1):108-115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/9428460/pubmed" id="9428460" target="_blank">9428460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30067928">
<a name="30067928"></a>Diallo T, Adjobimey M, Ruslami R, et al. Safety and side effects of rifampin versus isoniazid in children. <i>N Engl J Med</i>. 2018;379(5):454-463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30067928/pubmed" id="30067928" target="_blank">30067928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8412982">
<a name="8412982"></a>Drugs for Tuberculosis. <i>Med Lett Drugs Ther</i>. 1993;35(908):99-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/8412982/pubmed" id="8412982" target="_blank">8412982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6407604">
<a name="6407604"></a>Elansary EH, Earis JE. Rifampicin and adrenal crisis. <i>Br Med J (Clin Res Ed)</i>. 1983;286(6381):1861-1862. doi:10.1136/bmj.286.6381.1861-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/6407604/pubmed" id="6407604" target="_blank">6407604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17401268">
<a name="17401268"></a>El-Karaksy H, Mansour S, El-Sayed R, El-Raziky M, El-Koofy N, Taha G. Safety and efficacy of rifampicin in children with cholestatic pruritus. <i>Indian J Pediatr</i>. 2007;74(3):279-281. doi:10.1007/s12098-007-0044-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/17401268/pubmed" id="17401268" target="_blank">17401268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>J Thorac Dis</i>. 2018;10(5):3102-3118. doi:10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23060374">
<a name="23060374"></a>Farah N, Williams A, Joyce M, Bothamley GH, Rajakulasingam K. Rare immediate hypersensitivity to rifampicin in a patient with tuberculosis requiring drug discontinuation. <i>BMJ Case Rep</i>. 2012;2012:bcr-2012-006791. doi:10.1136/bcr-2012-006791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/23060374/pubmed" id="23060374" target="_blank">23060374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29776648">
<a name="29776648"></a>Fathallah N, Bellasfar N, Ammar H, et al. DRESS syndrome induced by rifampicin. <i>Therapie</i>. 2018;73(5):441-443. doi:10.1016/j.therap.2018.02.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/29776648/pubmed" id="29776648" target="_blank">29776648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31840241">
<a name="31840241"></a>Feng X, Ye X, Xu J, Li C. Mixed lichenoid and psoriasiform drug eruption induced by rifampicin. <i>Australas J Dermatol</i>. 2020;61(2):e231-e233. doi:10.1111/ajd.13222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/31840241/pubmed" id="31840241" target="_blank">31840241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666259">
<a name="26666259"></a>Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71(suppl 1):i1-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/26666259/pubmed" id="26666259" target="_blank">26666259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16503745">
<a name="16503745"></a>Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. <i>Expert Opin Drug Saf</i>. 2006;5(2):231-249. doi:10.1517/14740338.5.2.231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/16503745/pubmed" id="16503745" target="_blank">16503745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7537398">
<a name="7537398"></a>Furlan V, Perello L, Jacquemin E, et al. Interactions Between FK506 and Rifampicin or Erythromycin in Pediatric Liver Recipients. <i>Transplantation</i>. 1995;59(8):1217-1218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/7537398/pubmed" id="7537398" target="_blank">7537398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17021322">
<a name="17021322"></a>Gardner P. Clinical practice. Prevention of meningococcal disease [published correction appears in <i>N Engl J Med</i>. 2007;356(5):536]. <i>N Engl J Med</i>. 2006;355(14):1466‐1473. doi:10.1056/NEJMcp063561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/17021322/pubmed" id="17021322" target="_blank">17021322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19590173">
<a name="19590173"></a>Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. <i>Dermatology</i>. 2009;219(2):148‐154. doi:10.1159/000228334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/19590173/pubmed" id="19590173" target="_blank">19590173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother</i>. 2012;67(2):269-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8024298">
<a name="8024298"></a>Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. <i>Arch Dis Child</i>. 1993;69(1):141-143. doi:10.1136/adc.69.1.141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/8024298/pubmed" id="8024298" target="_blank">8024298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26831295">
<a name="26831295"></a>Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. <i>Rev Endocr Metab Disord</i>. 2016;17(3):343‐351. doi:10.1007/s11154-016-9328-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/26831295/pubmed" id="26831295" target="_blank">26831295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16144880">
<a name="16144880"></a>Gupta R, Wargo KA. Rifampin-induced thrombotic thrombocytopenic purpura. <i>Ann Pharmacother</i>. 2005;39(10):1761-1762. doi:10.1345/aph.1G219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/16144880/pubmed" id="16144880" target="_blank">16144880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32014989">
<a name="32014989"></a>Harlow CF, Meghji J, Martin L, Harris T, Kon OM. Rifampicin induced shock during re-exposure for treatment of latent tuberculosis. <i>BMJ Case Rep</i>. 2020;13(1):e232117. Corrected and republished in: <i>Drug Ther Bull</i>. 2020;58(10):157-159. doi:10.1136/bcr-2019-232117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/32014989/pubmed" id="32014989" target="_blank">32014989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22296864">
<a name="22296864"></a>Hashemi SH, Gachkar L, Keramat F, et al. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. <i>Int J Infect Dis</i>. 2012;16(4):e247-251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/22296864/pubmed" id="22296864" target="_blank">22296864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22302861">
<a name="22302861"></a>Havey TC, Cserti-Gazdewich C, Sholzberg M, Keystone JS, Gold WL. Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin. <i>Am J Trop Med Hyg</i>. 2012;86(2):264-267. doi:10.4269/ajtmh.2012.11-0598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/22302861/pubmed" id="22302861" target="_blank">22302861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9929528">
<a name="9929528"></a>Havlir DV and Barnes PF, “Tuberculosis in Patients With Human Immunodeficiency Virus Infection,” <i>N Engl J Med</i>, 1999, 340(5):367-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/9929528/pubmed" id="9929528" target="_blank">9929528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(suppl 2):ii1‐ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8686718">
<a name="8686718"></a>Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. <i>Am J Med</i>. 1996;101(1):68-76. doi:10.1016/s0002-9343(96)00070-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/8686718/pubmed" id="8686718" target="_blank">8686718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-8. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7564301">
<a name="7564301"></a>Herrera Trevilla P, Ortiz Jimenez E, Tena T, et al. Presence of Rifampicin in Urine Causes Cross-Reactivity With Opiates Using the KIMS Method. <i>J Anal Toxicol</i>. 1995;19(3):200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/7564301/pubmed" id="7564301" target="_blank">7564301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24918746">
<a name="24918746"></a>Hildebrand KJ, Atkinson A, Kitai I. Rifampin hypersensitivity in a 2-year-old child with successful rapid oral desensitization. <i>Pediatr Infect Dis J</i>. 2014;33(7):787. doi:10.1097/INF.0000000000000295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/24918746/pubmed" id="24918746" target="_blank">24918746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25505005">
<a name="25505005"></a>Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. <i>J Antimicrob Chemother</i>. 2015;70(4):1115-1123. doi:10.1093/jac/dku478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/25505005/pubmed" id="25505005" target="_blank">25505005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2689837">
<a name="2689837"></a>Holdiness MR. A review of the Redman syndrome and rifampicin overdosage. <i>Med Toxicol Adverse Drug Exp</i>. 1989;4(6):444-51. doi:10.1007/BF03259925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/2689837/pubmed" id="2689837" target="_blank">2689837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8350889">
<a name="8350889"></a>Iseman MD. Treatment of Multidrug-Resistant Tuberculosis. <i>N Engl J Med</i>. 1993;329(11):784-791.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/8350889/pubmed" id="8350889" target="_blank">8350889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30152252">
<a name="30152252"></a>Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. <i>N Engl J Med</i>. 2019;380(5):415-424. doi:10.1056/NEJMoa1808312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30152252/pubmed" id="30152252" target="_blank">30152252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6789927">
<a name="6789927"></a>Jenkins P, Emerson PA. Myopathy induced by rifampicin.<i> Br Med J (Clin Res Ed)</i>. 1981;283(6284):105-106. doi:10.1136/bmj.283.6284.105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/6789927/pubmed" id="6789927" target="_blank">6789927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28143754">
<a name="28143754"></a>Jia B, Zhang F, Pang P, et al. Brucella endocarditis: clinical features and treatment outcomes of 10 cases from Xinjiang, China. <i>J Infect</i>. 2017;74(5):512‐514. doi:10.1016/j.jinf.2017.01.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/28143754/pubmed" id="28143754" target="_blank">28143754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203783">
<a name="28203783"></a>Johnston JC, Campbell JR, Menzies D. Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and metaanalysis. <i>Clin Infect Dis</i>. 2017;64(9):1211-1220. doi:10.1093/cid/cix121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/28203783/pubmed" id="28203783" target="_blank">28203783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Karchmer.1">
<a name="Karchmer.1"></a>Karchmer AW, Chu VH. Antimicrobial therapy of prosthetic valve endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7028436">
<a name="7028436"></a>Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. <i>Drug Metab Rev</i>. 1981;12(1):159-218. doi:10.3109/03602538109011084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/7028436/pubmed" id="7028436" target="_blank">7028436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16452352">
<a name="16452352"></a>Khashu M, Osiovich H, Henry D, Al Khotani A, Solimano A, Speert DP. Persistent bacteremia and severe thrombocytopenia caused by coagulase-negative Staphylococcus in a neonatal intensive care unit. <i>Pediatrics</i>. 2006;117(2):340-348. doi:10.1542/peds.2005-0333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/16452352/pubmed" id="16452352" target="_blank">16452352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16953834">
<a name="16953834"></a>Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. <i>Liver Int</i>. 2006;26(8):943-948.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/16953834/pubmed" id="16953834" target="_blank">16953834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20224679">
<a name="20224679"></a>Kim JH, Moon JI, Kim JE, et al. Cutaneous leukocytoclastic vasculitis due to anti-tuberculosis medications, rifampin and pyrazinamide. <i>Allergy Asthma Immunol Res</i>. 2010;2(1):55-58. doi:10.4168/aair.2010.2.1.55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/20224679/pubmed" id="20224679" target="_blank">20224679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24587958">
<a name="24587958"></a>Kim DH, Choi YH, Kim HS, Yu JE, Koh YI. A case of serum sickness-like reaction and anaphylaxis - induced simultaneously by rifampin. <i>Allergy Asthma Immunol Res</i>. 2014;6(2):183-185. doi:10.4168/aair.2014.6.2.183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/24587958/pubmed" id="24587958" target="_blank">24587958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7849351">
<a name="7849351"></a>Kindelan JM, Serrano I, Jurado R, et al. Rifampin-Induced Severe Thrombocytopenia in a Patient With Pulmonary Tuberculosis. <i>Ann Pharmacother</i>. 1994;28(11):1304-1305.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/7849351/pubmed" id="7849351" target="_blank">7849351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12458578">
<a name="12458578"></a>Kobayashi K, Haruta T, Maeda H, Kubota M, Nishio T. Cerebral hemorrhage associated with vitamin K deficiency in congenital tuberculosis treated with isoniazid and rifampin. <i>Pediatr Infect Dis J</i>. 2002;21(11):1088-1090. doi:10.1097/00006454-200211000-00029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/12458578/pubmed" id="12458578" target="_blank">12458578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23411704">
<a name="23411704"></a>Koma Y, Goto K, Yoshida C, et al. Pneumonitis induced by rifampicin: a case report and literature review. <i>Intern Med</i>. 2013;52(4):473-477. doi:10.2169/internalmedicine.52.8997<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/23411704/pubmed" id="23411704" target="_blank">23411704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12403887">
<a name="12403887"></a>Kunichika N, Miyahara N, Kotani K, Takeyama H, Harada M, Tanimoto M. Pneumonitis induced by rifampicin. <i>Thorax</i>. 2002;57(11):1000-1001. doi:10.1136/thorax.57.11.1000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/12403887/pubmed" id="12403887" target="_blank">12403887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26407268">
<a name="26407268"></a>Kwara A, Enimil A, Gillani FS, et al. Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection. <i>J Pediatric Infect Dis Soc</i>. 2016;5(4):356-365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/26407268/pubmed" id="26407268" target="_blank">26407268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28060046">
<a name="28060046"></a>Li Y, Zhu Y, Zhong Q, Zhang X, Shu M, Wan C. Serious adverse reactions from anti-tuberculosis drugs among 599 children hospitalized for tuberculosis. <i>Pediatr Infect Dis J</i>. 2017;36(8):720-725. doi:10.1097/INF.0000000000001532<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/28060046/pubmed" id="28060046" target="_blank">28060046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30070375">
<a name="30070375"></a>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2019;69(1):394‐419. doi:10.1002/hep.30145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30070375/pubmed" id="30070375" target="_blank">30070375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34431119">
<a name="34431119"></a>Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2022;75(4):1012-1013. doi:10.1002/hep.32117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/34431119/pubmed" id="34431119" target="_blank">34431119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21217178">
<a name="21217178"></a>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children: executive summary. <i>Clin Infect Dis.</i> 2011;52(3):285-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/21217178/pubmed" id="21217178" target="_blank">21217178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7490442">
<a name="7490442"></a>Lundstrom TS, Sobel JD. Vancomycin, Trimethoprim-Sulfamethoxazole, and Rifampin. <i>Infect Dis Clin North Am</i>. 1995;9(3):747-767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/7490442/pubmed" id="7490442" target="_blank">7490442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17715477">
<a name="17715477"></a>Luzzati R, Giacomazzi D, Franchi F, Barcobello M, Vento S. Life-threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis. <i>South Med J</i>. 2007;100(8):854-856. doi:10.1097/SMJ.0b013e3180f60a57<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/17715477/pubmed" id="17715477" target="_blank">17715477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10228130">
<a name="10228130"></a>Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. <i>Am J Respir Crit Care Med</i>. 1999;159(5 Pt 1):1580-1584. doi:10.1164/ajrccm.159.5.9810034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/10228130/pubmed" id="10228130" target="_blank">10228130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10575418">
<a name="10575418"></a>Martínez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. <i>Medicine (Baltimore)</i>. 1999;78(6):361-369. doi:10.1097/00005792-199911000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/10575418/pubmed" id="10575418" target="_blank">10575418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23641931">
<a name="23641931"></a>Martins MA, Reis AM, Sales MF, et al. Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature. <i>BMC Pharmacol Toxicol</i>. 2013;14:27. doi:10.1186/2050-6511-14-27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/23641931/pubmed" id="23641931" target="_blank">23641931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):1444-1453. doi:10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2147086">
<a name="2147086"></a>Mimouni A, Hodak E, Mimouni M. Fixed drug eruption following rifampin treatment. <i>DICP</i>. 1990;24(10):947-948. doi:10.1177/106002809002401008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/2147086/pubmed" id="2147086" target="_blank">2147086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24275373">
<a name="24275373"></a>Mirsaeidi M, Schraufnagel D. Rifampin induced angioedema: a rare but serious side effect. <i>Braz J Infect Dis</i>. 2014;18(1):102-103. doi:10.1016/j.bjid.2013.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/24275373/pubmed" id="24275373" target="_blank">24275373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18332051">
<a name="18332051"></a>Moet FJ, Pahan D, Oskam L, Richardus JH; COLEP Study Group. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. <i>BMJ</i>. 2008;336(7647):761-764. doi:10.1136/bmj.39500.885752.BE<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/18332051/pubmed" id="18332051" target="_blank">18332051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2379538">
<a name="2379538"></a>Nahata MC, Fan-Havard P, Barson WJ, Bartkowski HM, Kosnik EJ. Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. <i>Eur J Clin Pharmacol</i>. 1990;38(5):515-517. doi:10.1007/BF02336694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/2379538/pubmed" id="2379538" target="_blank">2379538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8173129">
<a name="8173129"></a>Nahata MC, Morosco RS, Hipple TF. Effect of Preparation Method and Storage on Rifampin Concentration in Suspensions. <i>Ann Pharmacother</i>. 1994;28(2):182-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/8173129/pubmed" id="8173129" target="_blank">8173129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516382">
<a name="27516382"></a>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-e195. doi:10.1093/cid/ciw376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/27516382/pubmed" id="27516382" target="_blank">27516382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729908">
<a name="31729908"></a>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/31729908/pubmed" id="31729908" target="_blank">31729908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHDP.1">
<a name="NHDP.1"></a>National Hansen's Disease (Leprosy) Program (NHDP). Health Resources and Services Administration. Recommended treatment regimens. <a href="https://www.hrsa.gov/hansens-disease/diagnosis/recommended-treatment.html" target="_blank">https://www.hrsa.gov/hansens-disease/diagnosis/recommended-treatment.html</a>. Updated April 2018. Accessed May 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Clinical guideline. https://www.nice.org.uk/guidance/cg183. Published September 3, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25372213">
<a name="25372213"></a>Nelson J, Saggau DD, Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. <i>Retin Cases Brief Rep</i>. 2014;8(1):70-72. doi:10.1097/ICB.0000000000000007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/25372213/pubmed" id="25372213" target="_blank">25372213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7898260">
<a name="7898260"></a>Noble A. Antituberculous Therapy and Acute Liver Failure. <i>Lancet</i>. 1995;345(8953):867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/7898260/pubmed" id="7898260" target="_blank">7898260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11850651">
<a name="11850651"></a>Orisakwe OE, Dioka CE, Orish CN, et al. Charcoal and Rifampicin Pharmacokinetics. <i>Am J Therapeut</i>. 1995;68-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/11850651/pubmed" id="11850651" target="_blank">11850651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2013;56(1):e1‐e25. doi:10.1093/cid/cis803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.1">
<a name="Osmon.1"></a>Osmon DR, Tande AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23901086">
<a name="23901086"></a>Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. <i>J Infect Dis</i>. 2013;208(9):1464-1473. doi:10.1093/infdis/jit352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/23901086/pubmed" id="23901086" target="_blank">23901086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11422169">
<a name="11422169"></a>Patel GK, Anstey AV. Rifampicin-induced lupus erythematosus. <i>Clin Exp Dermatol</i>. 2001;26(3):260-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/11422169/pubmed" id="11422169" target="_blank">11422169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7316759">
<a name="7316759"></a>Plomp TA, Battista HJ, Unterdorfer H, et al. A Case of Fatal Poisoning by Rifampicin. <i>Arch Toxicol</i>. 1981;48(4):245-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/7316759/pubmed" id="7316759" target="_blank">7316759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Poupon.1">
<a name="Poupon.1"></a>Poupon R, Chopra S. Pruritus associated with cholestasis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9809743">
<a name="9809743"></a>Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention. <i>MMWR Recomm Rep</i>. 1998;47(RR-20):1-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/9809743/pubmed" id="9809743" target="_blank">9809743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35139280">
<a name="35139280"></a>Pries-Heje MM, Wiingaard C, Ihlemann N, et al. Five-year outcomes of the partial oral treatment of endocarditis (POET) trial. <i>N Engl J Med</i>. 2022;386(6):601-602. doi:10.1056/NEJMc2114046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/35139280/pubmed" id="35139280" target="_blank">35139280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11001270">
<a name="11001270"></a>Rajagopalan S, Yoshikawa TT. Tuberculosis in long-term-care facilities. <i>Infect Control Hosp Epidemiol</i>. 2000;21(9):611-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/11001270/pubmed" id="11001270" target="_blank">11001270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33129378">
<a name="33129378"></a>Richardus JH, Tiwari A, Barth-Jaeggi T, et al. Leprosy post-exposure prophylaxis with single-dose rifampicin (LPEP): an international feasibility programme.<i> Lancet Glob Health</i>. 2021;9(1):e81-e90. doi:10.1016/S2214-109X(20)30396-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/33129378/pubmed" id="33129378" target="_blank">33129378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rifadin.1">
<a name="Rifadin.1"></a>Rifadin capsules and Rifadin IV (rifampin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanofi.1">
<a name="Sanofi.1"></a>Rifadin (rifampin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; December 2020.</div>
</li>
<li>
<div class="reference">
                  Rifampin capsules [prescribing information]. Congers, NY: Chartwell RX, LLC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23328960">
<a name="23328960"></a>Rodriguez-Guerineau L, Salvia-Roigés MD, León-Lozano M, Rodríguez-Miguélez JM, Figueras-Aloy J. Combination of vancomycin and rifampicin for the treatment of persistent coagulase-negative staphylococcal bacteremia in preterm neonates. <i>Eur J Pediatr</i>. 2013;172(5):693-697. doi:10.1007/s00431-012-1927-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/23328960/pubmed" id="23328960" target="_blank">23328960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valeant.1">
<a name="Valeant.1"></a>Rofact (rifampin) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15155180">
<a name="15155180"></a>Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. <i>Antimicrob Agents Chemother</i>. 2004;48(6):1921-1933. doi:10.1128/AAC.48.6.1921-1933.2004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/15155180/pubmed" id="15155180" target="_blank">15155180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11473672">
<a name="11473672"></a>Rossert J. Drug-induced acute interstitial nephritis. <i>Kidney Int</i>. 2001;60(2):804-817. doi:10.1046/j.1523-1755.2001.060002804.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/11473672/pubmed" id="11473672" target="_blank">11473672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1308530">
<a name="1308530"></a>Salafia A, Candida. Rifampicin induced flu-syndrome and toxic psychosis. <i>Indian J Lepr</i>. 1992;64(4):537-539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/1308530/pubmed" id="1308530" target="_blank">1308530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32789061">
<a name="32789061"></a>Sanwal C, Kaldas A, Surani S, Bailey M. Rifampin-induced acute intravascular hemolysis leading to heme pigment-related kidney injury. <i>Cureus</i>. 2020;12(7):e9120. doi:10.7759/cureus.9120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/32789061/pubmed" id="32789061" target="_blank">32789061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17021358">
<a name="17021358"></a>Saukkonen JJ, Cohn DL, Jasmer RM, et al; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. <i>Am J Respir Crit Care Med</i>. 2006;174(8):935-952. doi:10.1164/rccm.200510-1666ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/17021358/pubmed" id="17021358" target="_blank">17021358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25323272">
<a name="25323272"></a>Shahul HA, Manu MK, Mohapatra AK, Mathew M. Rifampicin-induced lichenoid eruptions. <i>BMJ Case Rep</i>. 2014;2014:bcr2013202346. doi:10.1136/bcr-2013-202346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/25323272/pubmed" id="25323272" target="_blank">25323272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12162600">
<a name="12162600"></a>Shama A, Patole SK, Whitehall JS. Intravenous rifampicin in neonates with persistent staphylococcal bacteraemia. <i>Acta Paediatr</i>. 2002;91(6):670-673. doi:10.1080/080352502760069098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/12162600/pubmed" id="12162600" target="_blank">12162600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24450829">
<a name="24450829"></a>Shebe K, Ngwanya MR, Gantsho N, Lehloenya RJ. Severe recurrence of drug rash with eosinophilia and systemic symptoms syndrome secondary to rifampicin patch testing in a human immunodeficiency virus-infected man. <i>Contact Dermatitis</i>. 2014;70(2):125-127. doi:10.1111/cod.12155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/24450829/pubmed" id="24450829" target="_blank">24450829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33539388">
<a name="33539388"></a>Shin HJ, Chang JS, Kim MS, et al. Hypersensitivity reactions to multiple anti-tuberculosis drugs. <i>PLoS One</i>. 2021;16(2):e0246291. doi:10.1371/journal.pone.0246291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/33539388/pubmed" id="33539388" target="_blank">33539388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis. </i>2014;58(10):1496]. <i>Clin Infect Dis.</i> 2012;55(10):e86-e102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29410254">
<a name="29410254"></a>Siripassorn K, Ruxrungtham K, Manosuthi W. Successful drug desensitization in patients with delayed-type allergic reactions to anti-tuberculosis drugs. <i>Int J Infect Dis</i>. 2018;68:61-68. doi:10.1016/j.ijid.2018.01.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/29410254/pubmed" id="29410254" target="_blank">29410254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18321957">
<a name="18321957"></a>Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. <i>BMJ</i>. 2008;336(7646):701‐704. doi:10.1136/bmj.39497.500903.25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/18321957/pubmed" id="18321957" target="_blank">18321957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30910891">
<a name="30910891"></a>Smith PB, Cotten CM, Hudak ML, et al. Rifampin Pharmacokinetics and Safety in Preterm and Term Infants. <i>Antimicrob Agents Chemother</i>. 2019;63(6):e00284-19. doi:10.1128/AAC.00284-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30910891/pubmed" id="30910891" target="_blank">30910891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10585793">
<a name="10585793"></a>Solera J, Lozano E, Martínez-Alfaro E, Espinosa A, Castillejos ML, Abad L. Brucellar spondylitis: review of 35 cases and literature survey. <i>Clin Infect Dis</i>. 1999;29(6):1440‐1449. doi:10.1086/313524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/10585793/pubmed" id="10585793" target="_blank">10585793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8540716">
<a name="8540716"></a>Solera J, Rodríguez-Zapata M, Geijo P, et al. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to <i>Brucella melitensis</i>. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. <i>Antimicrob Agents Chemother</i>. 1995;39(9):2061-2067. doi:10.1128/aac.39.9.2061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/8540716/pubmed" id="8540716" target="_blank">8540716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.2020a">
<a name="Spach.2020a"></a>Spach DH. Clinical features, diagnosis, and treatment of Bartonella quintana infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.2020b">
<a name="Spach.2020b"></a>Spach DH. Endocarditis caused by Bartonella. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.2020c">
<a name="Spach.2020c"></a>Spach DH, Kaplan SL. Treatment of cat scratch disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3287309">
<a name="3287309"></a>Starke JR. Modern Approach to the Diagnosis and Treatment of Tuberculosis in Children. <i>Pediatr Clin North Am</i>. 1988;35(3):441-464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/3287309/pubmed" id="3287309" target="_blank">3287309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2124671">
<a name="2124671"></a>Starke JR. Multidrug Therapy for Tuberculosis in Children. <i>Pediatr Infect Dis J</i>. 1990;9(11):785-793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/2124671/pubmed" id="2124671" target="_blank">2124671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25904367">
<a name="25904367"></a>Sterling TR, Moro RN, Borisov AS, et al; Tuberculosis trials consortium. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. <i>Clin Infect Dis</i>. 2015;61(4):527-535. doi:10.1093/cid/civ323<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/25904367/pubmed" id="25904367" target="_blank">25904367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32053584">
<a name="32053584"></a>Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. <i>MMWR Recomm Rep</i>. 2020;69(1):1‐11. doi:10.15585/mmwr.rr6901a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/32053584/pubmed" id="32053584" target="_blank">32053584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26518065">
<a name="26518065"></a>Strunk AK, Ciesek S, Schmidt JJ, et al. Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. <i>Int J Infect Dis</i>. 2016;42:1-3. doi:10.1016/j.ijid.2015.10.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/26518065/pubmed" id="26518065" target="_blank">26518065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30567221">
<a name="30567221"></a>Sveroni D, Stefos A, Rigopoulou EI, Dalekos GN. Rifampicin: not always an innocent drug. <i>BMJ Case Rep</i>. 2018;11(1):e227356. doi:10.1136/bcr-2018-227356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30567221/pubmed" id="30567221" target="_blank">30567221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26603634">
<a name="26603634"></a>Syrigou E, Grapsa D, Nanou E, et al. Anaphylaxis during rapid oral desensitization to rifampicin. <i>J Allergy Clin Immunol Pract</i>. 2016;4(1):173-174. doi:10.1016/j.jaip.2015.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/26603634/pubmed" id="26603634" target="_blank">26603634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8285624">
<a name="8285624"></a>Tan TQ, Mason EO Jr, Ou CN, et al. Use of Intravenous Rifampin in Neonates With Persistent Staphylococcal Bacteremia. <i>Antimicrob Agents Chemother</i>. 1993;37(11):2401-2406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/8285624/pubmed" id="8285624" target="_blank">8285624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3889257">
<a name="3889257"></a>Tanz RR, Shulman ST, Barthel MJ, Willert C, Yogev R. Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. <i>J Pediatr</i>. 1985;106(6):876-880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/3889257/pubmed" id="3889257" target="_blank">3889257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15636299">
<a name="15636299"></a>Thrupp L, Bradley S, Smith P, et al. Tuberculosis prevention and control in long-term-care facilities for older adults. <i>Infect Control Hosp Epidemiol</i>. 2004;25(12):1097-1108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/15636299/pubmed" id="15636299" target="_blank">15636299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17995946">
<a name="17995946"></a>Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. <i>J Gastroenterol Hepatol</i>. 2008;23(2):192-202. doi:10.1111/j.1440-1746.2007.05207.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/17995946/pubmed" id="17995946" target="_blank">17995946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LTBI.1">
<a name="LTBI.1"></a>Treatment of Latent Tuberculosis Infection (LTBI), Last Updated: April 8, 2004. <a href="https://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm" target="_blank">http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm</a>. Accessed February 16, 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. Published online February 14, 2017. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3382314">
<a name="3382314"></a>Umeki S. Rifampicin and pulmonary fibrosis. <i>Arch Intern Med</i>. 1988;148(7):1663-1667. doi:10.1001/archinte.148.7.1663b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/3382314/pubmed" id="3382314" target="_blank">3382314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Accessed May 26, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated February 17, 2022. Accessed January 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>.Updated December 9, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19590174">
<a name="19590174"></a>van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. <i>Dermatology</i>. 2009;219(2):143‐147. doi:10.1159/000228337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/19590174/pubmed" id="19590174" target="_blank">19590174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1347579">
<a name="1347579"></a>Van Scoy RE, Wilkowske CJ. Antituberculosis Agents. <i>Mayo Clin Proc</i>. 1992;67(2):179-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/1347579/pubmed" id="1347579" target="_blank">1347579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9545154">
<a name="9545154"></a>Vesely JJ, Pien FD, Pien BC. Rifampin, a Useful Drug for Nonmycobacterial Infections. <i>Pharmacotherapy</i>. 1998;18(2):345-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/9545154/pubmed" id="9545154" target="_blank">9545154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4606454">
<a name="4606454"></a>Vorherr H. Drug excretion in breast milk. <i>Postgrad Med</i>. 1974;56(4):97-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/4606454/pubmed" id="4606454" target="_blank">4606454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7606073">
<a name="7606073"></a>Walker-Renard P. Pruritus Associated With Intravenous Rifampin. <i>Ann Pharmacother</i>. 1995;29(3):267-268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/7606073/pubmed" id="7606073" target="_blank">7606073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32(suppl 2):S32-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275849">
<a name="30275849"></a>Warrington R, Silviu-Dan F, Wong T. Drug allergy. <i>Allergy Asthma Clin Immunol</i>. 2018;14(suppl 2):60. doi:10.1186/s13223-018-0289-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30275849/pubmed" id="30275849" target="_blank">30275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36052413">
<a name="36052413"></a>Wildenthal JA, Atkinson A, Lewis S, et al. Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs.<i> Clin Infect Dis</i>. 2023;76(3):487-496. doi:10.1093/cid/ciac714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/36052413/pubmed" id="36052413" target="_blank">36052413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6371210">
<a name="6371210"></a>Wong P, Bottoroff MB, Heritage RW, et al. Acute Rifampin Overdose: A Pharmacokinetic Study and Review of the Literature. <i>J Pediatr</i>. 1984;104(5):781-783.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/6371210/pubmed" id="6371210" target="_blank">6371210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Brucellosis in humans and animals. http://www.who.int/csr/resources/publications/Brucellosis.pdf. Published 2006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). Guidelines for the diagnosis, treatment and prevention of leprosy. https://apps.who.int/iris/bitstream/handle/10665/274127/9789290226383-eng.pdf?ua=1. Published October 2018. Accessed January 22, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.8">
<a name="WHO.8"></a>World Health Organization (WHO). Leprosy/Hansen disease: contact tracing and post-exposure prophylaxis. https://www.who.int/publications/i/item/9789290228073. Published 2017. Accessed January 22, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.5">
<a name="WHO.5"></a>World Health Organization (WHO). Treatment of tuberculosis guidelines. 4th edition. 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.6">
<a name="WHO.6"></a>World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 1: prevention. https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment. Published 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.7">
<a name="WHO.7"></a>World Health Organization (WHO). WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization; 2019. https://www.who.int/publications/i/item/9789241550529
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17029130">
<a name="17029130"></a>Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2006;43(9):1089-1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/17029130/pubmed" id="17029130" target="_blank">17029130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28719501">
<a name="28719501"></a>Yang H, Enimil A, Gillani FS, et al. Evaluation of the adequacy of the 2010 revised World Health Organization recommended dosages of the first-line antituberculosis drugs for children: adequacy of revised dosages of TB drugs for children. <i>Pediatr Infect Dis J</i>. 2018;37(1):43-51. doi:10.1097/INF.0000000000001687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/28719501/pubmed" id="28719501" target="_blank">28719501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27373553">
<a name="27373553"></a>Ye YM, Hur GY, Kim SH, et al. Drug-specific CD4+ T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. <i>Br J Dermatol</i>. 2017;176(2):378-386. doi:10.1111/bjd.14839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/27373553/pubmed" id="27373553" target="_blank">27373553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12569078">
<a name="12569078"></a>Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. <i>Am J Respir Crit Care Med</i>. 2003;167(11):1472-1477. doi:10.1164/rccm.200206-626OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/12569078/pubmed" id="12569078" target="_blank">12569078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10512405">
<a name="10512405"></a>Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer FM. Use of rifampin for severe pruritus in children with chronic cholestasis. <i>J Pediatr Gastroenterol Nutr</i>. 1999;29(4):442-447. doi:10.1097/00005176-199910000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/10512405/pubmed" id="10512405" target="_blank">10512405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17052297">
<a name="17052297"></a>Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. <i>Respirology</i>. 2006;11(6):699-707. doi:10.1111/j.1440-1843.2006.00941.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/17052297/pubmed" id="17052297" target="_blank">17052297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32169513">
<a name="32169513"></a>Yonkof JR, Tapke DE, Fox CC, Ogbogu PU. Successful use of rifampin in a patient with Stevens-Johnson syndrome to rifabutin. <i>Ann Allergy Asthma Immunol</i>. 2020;124(6):624-626. doi:10.1016/j.anai.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/32169513/pubmed" id="32169513" target="_blank">32169513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1740604">
<a name="1740604"></a>Yoshikawa TT. Tuberculosis in Aging Adults. <i>J Am Geriatr Soc</i>. 1992;40(2):178-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/1740604/pubmed" id="1740604" target="_blank">1740604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32989000">
<a name="32989000"></a>Xu N, Yang JX, Yang J. Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China. <i>Eur J Hosp Pharm</i>. 2022;29(4):217-221. doi:10.1136/ejhpharm-2020-002433<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/32989000/pubmed" id="32989000" target="_blank">32989000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28768443">
<a name="28768443"></a>Zheng N, Wang W, Zhang JT, et al. Neurobrucellosis. <i>Int J Neurosci</i>. 2018;128(1):55‐62. doi:10.1080/00207454.2017.1363747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/28768443/pubmed" id="28768443" target="_blank">28768443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30455229">
<a name="30455229"></a>Zimmerli W, Sendi P. Role of rifampin against staphylococcal biofilm infections <i>in vitro</i>, in animal models, and in orthopedic-device-related infections. <i>Antimicrob Agents Chemother</i>. 2019;63(2):e01746-18. doi:10.1128/AAC.01746-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/30455229/pubmed" id="30455229" target="_blank">30455229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9605897">
<a name="9605897"></a>Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. <i>JAMA</i>. 1998;279(19):1537‐1541. doi:10.1001/jama.279.19.1537<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/9605897/pubmed" id="9605897" target="_blank">9605897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25640693">
<a name="25640693"></a>Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. <i>J Eur Acad Dermatol Venereol</i>. 2015;29(4):619-644. doi:10.1111/jdv.12966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rifampin-rifampicin-pediatric-drug-information/abstract-text/25640693/pubmed" id="25640693" target="_blank">25640693</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12767 Version 533.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
